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Superoxide dismutase 1 (SOD1) is an enzyme responsible for intracellular breakdown 
of toxic reactive oxygen species in prokaryotes and eukaryotes. Mutations in SOD1 are 
linked to the motor neurone disease Amyotrophic lateral sclerosis (ALS), with around 
20% of familial (fALS) cases and, it is proposed, a significant proportion of sporadic 
cases caused by SOD1 mutations, however the mechanism of neuronal death remains 
unknown. Misfolding and aggregation of SOD1 leading to a ‘toxic gain of function’ is 
the most widely accepted mechanism, but further work is needed. To gain new 
insights into the underlying mechanism of cell toxicity, I am using two model systems: 
the yeast Saccharomyces cerevisiae and the nematode worm Caenorhabditis elegans. 
One hypothesis being tested was proposed by Ghadge et al. (2006) who reported that 
truncated forms of SOD1 (both wild type and fALS–linked mutants) form toxic 
aggregates in spinal cords of chick embryos, hypothesising that proteolytic digestion of 
unstable mutant SOD1 creates these toxic fragments. My project aims to elucidate 
how fALS–linked SOD1 mutants and SOD1 truncations exert toxicity on S. cerevisiae 
and C. elegans. In S. cerevisiae, SOD1 truncations do not specifically localise to, or 
disrupt the functioning of, mitochondria nor reduce viability of yeast although cell 
growth is slowed. Conversely, a motor-defective phenotype is exhibited in transgenic 
fALS–linked SOD1 mutant (G85R) C. elegans accompanied by vulval defects, which lead 
to reduced lifespan. My findings suggest that amino acid supplementation of G85R C. 
elegans mutants improves their motor function and vulval defects, implicating a role of 
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1.1 Background of ALS 
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing and fatal motor neurone 
disease characterized by degeneration of motor neurones. Progression of ALS leads to 
muscle atrophy, fasciculations, loss of voluntary muscle control and eventual death, on 
average occurring 5 years after the presentation of symptoms.  
In around 90% of cases, the disease manifests sporadically and with no apparent cause 
whereas in the other 10% of cases, the disease is inherited in an autosomal dominant 
manner; this inherited form is known as familial ALS (fALS). Approximately a third of 
familial ALS cases are caused by mutations in the gene C9orf72, and another 20% of 
cases are a result of mutation in the superoxide dismutase 1 gene, SOD1. 
It was previously thought that mutations in the SOD1 gene caused ALS due to the gene 
product losing its function or having an increased tendency to aggregate, thus resulting 
in neuronal cell death. More recent evidence suggests that the mutant SOD1 gene 
product may cause cell death by exhibiting a toxic function not observed in the wild 
type (Bleackley et al., 2011).  
1.2 Introduction to superoxide dismutases 
In mammals and yeast alike, superoxide dismutase (SOD) enzymes are essential for 
catalysing the breakdown of toxic reactive oxygen species (ROS) into non-toxic 
substances within cells. 
In eukaryotes, ROS are formed as by-products of the electron transport chain, released 
into the mitochondrial matrix and inter-membrane space (IMS) by NADH 
dehydrogenase enzyme and ubisemiquinone anion (Sturtz et al., 2001), and also from 
lack of regulation of intracellular metal pools. If not broken down, ROS can cause 
damage to essential cellular components leading to cell death.  
Sod1p, the gene product of the SOD1 gene, is a homodimer consisting of two identical 
polypeptide subunits, each containing both a copper and a zinc ion. Sod1p makes up 
90% of the total superoxide dismutase within human cells (Noor et al., 2002). SOD are 
highly evolutionarily conserved, with yeast Sod1p being the orthologue of human 
Sod1p. The human and yeast orthologues are show similar mechanisms of maturation 
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and are structurally similar; the human protein consists of 154 amino acids and 
contains two cysteine residues required for protein stability, whereas the yeast 
orthologue consists of 153 amino acids and has two proline residues necessary for 
Ccs1p binding. Prokaryotes and eukaryotes both express a form of cytosolic SOD1 
protein. Again, in prokaryotes and eukaryotes there exists another SOD enzyme known 
as Sod2p, which is a mitochondrial protein with a manganese ion in its active site; 
humans express a form of Sod2p which is orthologous to yeast Sod2p. However unlike 
yeast, mammalian cells express an additional SOD known as Sod3p, which consists of 
four subunits containing copper and zinc ions and is located extracellularly.  
Sod1p is known as the Cu/Zn superoxide dismutase as it relies on the binding and 
incorporation of copper and zinc ions into its active site in order to form the mature 
and active SOD1 enzyme. The presence of transition metal ions in all superoxide 
dismutases is essential for their enzymatic ability to detoxify ROS due to the tendency 
of transition metals to readily exchange electrons with ROS by way of redox reactions 
(Askwith et al., 1998).   
1.3 Interaction between Sod1p and Ccs1p 
The activity of Sod1p relies heavily on the copper chaperone for SOD1, Ccs1p, a 
metallo-chaperone which mediates maturation of Sod1p and its correct folding (Sturtz 
et al., 2001).  
Structurally, Ccs1p consists of three domains: the first domain contains a copper-
binding motif and is utilised for binding copper when the availability of copper within 
the cell is scarce (Puig and Thiele, 2002). The second domain forms the majority of the 
protein and has a region of high homology (around 50% identity) to Sod1p’s overall 
structure (Bleackley et al., 2011) – this region is responsible for the protein’s 
interaction with Sod1p. The third domain contains a CxC motif which allows donation 
of the copper ion to Sod1p.  
In S. cerevisiae, Ccs1p bound to a copper ion (Cu-Ccs1p) interacts specifically with 
immature Sod1p to insert the copper ion into its active site (Furukawa et al., 2004); 
interaction with Cu-Ccs1p also catalyses the reaction of Sod1p with oxygen to form an 
intra-molecular disulphide bond within Sod1p by facilitating oxidation of Sod1p 
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cysteine residues. Zinc binding to 
Sod1p stabilizes the incorporation of 
copper into the protein (Bleackley et 
al., 2011). When the interaction 
between immature Sod1p and Ccs1p 
is disrupted, improper formation of 
the disulphide bond results in a 
misfolded protein prone to 
aggregation. Alternatively, formation 
of the disulphide bond before 
incorporation of a copper ion results 
in Ccs1p no longer able to activate 
Sod1p, leaving it in an immature 
form. Immature SOD1 proteins are 
more susceptible to oxidative 
damage so it is important that they 
correctly undergo copper and zinc acquisition in addition to disulphide bond formation 
and dimerization to form the mature SOD1 protein, which is much more stable.  Sod1p 
is considered a cytosolic protein but around 1-5% of cellular Sod1p localizes to 
mitochondrial IMS to reduce oxidative damage caused by ROS (Sturtz et al., 2001). 
Sod1p also localizes to various other organelles in small amounts to perform its 
function.  
Generally, the human and yeast forms of Sod1p function similarly yet an important 
difference is that yeast Sod1p activation is dependent on Ccs1p whereas human Sod1p 
can be activated by other mechanisms (Bastow et al., 2011). Activation of SOD1 is 
suggested to be regulated by glutathionylation, performed by GSH in both yeast Ccs1p-
dependent and human Ccs1p-independent processes (Mannarino et al., 2011; Brasil et 
al., 2013). 
1.4 Intra-cellular copper transport facilitates maturation of Sod1p 
Multiple studies by other authors have demonstrated that Sod1p transport into 
mitochondria is optimal while still in its immature ‘apo’ form, prior to disulphide bond 
Figure 1.1: Interaction between yeast Sod1p 
and Ccs1p. The Sod1p monomer is shown in 
green, while Ccs1p domains 1, 2 and 3 are 
shown in pink, blue and yellow respectively. 
Ball-and-stick representations indicate cysteine 
residues, the gray sphere indicating a zinc ion 
(Lamb et al., 2001). 
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formation which is essential for the enzyme’s activity. In its apo form, Sod1p transport 
through the mitochondrial outer membrane is facilitated by Ccs1p (Furukawa et al., 
2004). However, it is hypothesised that once inside the mitochondrial IMS, maturation 
of SOD1 by the acquisition of metal ions, mediated by Ccs1p, causes Sod1p to be 
unable to pass through the mitochondrial outer membrane thus preventing 
translocation of Sod1p back into the cytoplasm. Equally, incorporation of metal ions 
into Sod1p while still in the cytoplasm may prevent its translocation into the 
mitochondria (Sturtz et al., 2001).  
In order for Sod1p to mature inside the mitochondrial IMS, copper ions must be 
present within mitochondria; subsequently, delivery of copper to the mitochondria is 
essential. In S. cerevisiae, a copper pool exists in the cell’s cytoplasm which serves as 
the source of copper for processes occurring both in the cytoplasm and in organelles 
as required (Cobine et al., 2006).  Since copper has high redox potential and could 
therefore be toxic to the cell, its concentration and transport must be tightly regulated 
(Kawamata and Manfredi, 2010). Metallo-thioneines Cup1p and Crs5p located in the 
cytoplasm are responsible for regulating this pool of free copper ions. 
 Metallo-chaperones such as Ccs1p and Atx1p transport copper ions from the 
cytoplasmic copper pool  to their required areas by protein-mediated transfer, Ccs1p 
carrying it to Sod1p and Atx1p carrying it to the Ccc2p transporter in post-Golgi 
vesicles for generation of cell membrane proteins.   
It had been suggested that metallo-chaperones Ccs1p and Cox17p were able to 
transport copper from the cytoplasm to the mitochondria since these proteins exist in 
both areas of the cell (Puig and Thiele, 2002). The idea of copper transport by Cox17p 
arose from research relating to cytochrome oxidase (COX), a mitochondrial 
transmembrane protein whose catalytic subunits Cox1p and Cox2p both require 
copper as a cofactor. Their acquisition of copper is facilitated by copper chaperone 
Cox17p which delivers copper specifically to these COX subunits, located in the 
mitochondrial IMS, for their assembly. Research by other authors has demonstrated 
that Cox17p is present in the cytosol as well as the mitochondrial IMS; since 
metallation of Cox1p and Cox2p occurs only within the mitochondrial IMS, this 
suggests that the cytosolic Cox17p is also able to deliver copper to COX subunits in the 
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mitochondrial IMS. However, this theory was dispelled by the finding that in yeast 
CCS1 and COX17 deletion mutants, mitochondrial copper concentrations were no 
different to that of the wild type. 
More recent research has elucidated that in both yeast and mouse cells, a separate 
copper pool is located in the mitochondrial matrix, which supplies copper to the IMS. 
Copper in the matrix pool is bound to non-proteinaceous ligands which may be 
accountable for the translocation of copper from the cytoplasm to the mitochondrial 
matrix pool. It is also believed that various additional transporters transfer copper 
from the matrix pool to other areas of the mitochondria (Cobine et al., 2006).  
This evidence suggests that once inside the mitochondrial IMS, apo-Sod1p is 
metallated by Ccs1p using copper supplied by the mitochondrial matrix copper pool 
and undergoes disulphide bond formation, giving rise to mature Sod1p. 
1.5 Mechanisms of SOD1-mediated toxicity 
1.5.1 Mitochondrial dysfunction and oxidative damage. 
Null mutations in SOD1, which produce either a non-functional protein or no gene 
product at all, display significant negative effects on yeast cells, with increased 
sensitivity to oxidative stress causing the mutant-expressing cells unable to grow well 
under aerobic conditions. Defects in mitochondrial function are demonstrated by the 
mutant’s impaired ability to grow on non-fermentable carbons sources, as a result of a 
defect in the electron transport chain. Low viability of null mutants growing in the 
stationary phase can be attributed to their inability to synthesize mitochondrial 
proteins such as mitochondrial aconitase, an enzyme involved in the citric acid cycle. 
SOD1 null mutant strains exhibit a deficiency in mitochondrial aconitase, rendering 
them unable to generate enough energy and nutrients to survive in the aerobic 
environment during the stationary phase (Longo et al., 1996; Cherry et al., 2012). 
In addition, SOD1 null mutants are auxotrophic for a number of amino acids; 
auxotrophy defines the inability of an organism to synthesize organic compounds 
essential for its growth. In particular, SOD1 mutants are strongly auxotrophic for 
methionine and lysine and show variable auxotrophy for leucine. Some attribute these 
effects due to oxidative damage to metabolic enzymes involved in amino acid 
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biosynthesis (Cherry et al., 2012), however it has also been suggested that mutations 
Sod1p may directly affect metabolic signalling (Bastow, 2013). Furthermore, other 
evidence suggests that Sod1p mutation may alter metal ion homeostasis, due to the 
finding that over-expression of ATX1 or ATX2 genes encoding metallo-chaperones can 
suppress the oxidative damage observed in SOD1 mutants (Cherry et al., 2012). The 
subsequent result of mutant Sod1p expression is a range of mitochondrial pathologies 
including damage to mitochondrial DNA and enzymes of the electron transport chain 
in addition to atypical mitochondrial morphology. These mitochondrial defects 
affecting overall cellular function, combined with the oxidative damage resulting from 
ROS, contribute to ALS (Sturtz et al., 2001).  
Furthermore, Wong et al. (1995) found that in mice, mitochondrial abnormalities 
resulting from mutant Sod1p expression lead to unexpected formation of vacuoles, in 
a phenomenon known as vacuolation. These abnormalities also had profound effects 
on the nervous system overall, since distribution and accumulation of SOD1 G37R 
mutant protein, a fALS-associated mutation, occurred in the same tissues as the wild 
type Sod1p. Mice expressing the mutant SOD1 protein showed progressive 
degeneration of motor neurons in the brain stem and lumbar, thoracic and cervical 
regions of the spinal cord. At a cellular level, mutant SOD1 mice showed noticeable 
vacuolation particularly in dendrites of the spinal cord and some in the motor neurone 
cell bodies, leading to a significantly reduced number of motor neurones in the lumbar 
of the spinal cord. The degree of vacuolation in dendrites and axons was sufficient to 
disrupt the cellular cytoskeleton and some axonal swelling was observed. The authors 
hypothesised that the vacuolation observed was in fact from degenerated 
mitochondria, damaged by mutant Sod1p. It was again noted that the Sodp1 mutant 
still retained the function of the wild type protein, suggesting this mitochondrial 
degeneration was due to the Sod1p mutant having a gain of function and that mutant 
Sod1p may target mitochondria.  
1.5.2 Mutant SOD1 aggregation. 
Studies have demonstrated that in mice, mutant SOD1 proteins associated with 
familial ALS is also shown to have a higher tendency to oligomerize than the wild type 
protein, causing accumulation and formation of intracellular protein aggregates 
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(Seetharaman et al., 2011). Evidence from these studies suggests that it is immature 
Sod1p mutants that form such aggregates, a result of disrupted interaction between 
Sod1p and Ccs1p which prevents Sod1p maturation. Further evidence has discovered 
that in mouse models expressing both fALS-associated mutant and wild type Sod1p, 
wild type Sod1p was not sufficient to overcome the pathologies exerted by its mutant 
counterpart, leading to the conclusion that the mutant Sod1p had in fact gained a toxic 
function rather than simply losing its protective function (Bleackley and MacGillivray, 
2011; Wang et al., 2003).  
Other studies have shown that it is only insoluble Sod1p mutants that form protein 
aggregates within cells (Wang et al., 2005). In mice, multiple different insoluble Sod1p 
mutants showed aggregation in somatodendritic compartments of the spinal cord 
motor neurons in particular, whereas the presence of soluble Sod1p mutants in these 
areas was ‘virtually undetectable’. Importantly, there was no evidence of the insoluble 
mutant’s presence in distal nerve fibres, showing that direct interaction between the 
mutant protein and the nerve axon is not necessary for toxicity to be observed. 
1.5.3 Mutant SOD1 affects amino acid regulation. 
SOD1 mutants in yeast display up-regulated translation of general amino acid control 
(GAAC) pathway signalling molecule, Gcn4, supporting the hypothesis that SOD1 
mutation causes metabolic defects (Bastow, 2013). GAAC is an evolutionarily 
conserved pathway that occurs in eukaryotic cells when they are under amino acid 
starvation conditions. Activation of GAAC facilitates specific translation of amino acids 
to restore homeostasis within the cell. 
Gcn2 is the initiator of GAAC, and is activated in response to two factors: amino acid 
starvation and oxidative stress. In both cases, the cellular response is the activation of 
Gcn2 which phosphorylates elF2α resulting in inhibition of mRNA translation initiation. 
In the case of amino acid starvation, elF2α phosphorylation leads to increased 
expression of transcription factor, Gcn4. Gcn4 activates various genes required for 
amino acid biosynthesis pathways in order to increase the cell’s synthesis of amino 
acids. By this mechanism, the cell decreases general protein synthesis and specifically 
increases amino acid biosynthesis, a process observed not only in yeast but also 
mammalian cells.  
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Under oxidative stress conditions, phosphorylation of elF2α leads to dose-dependent 
inhibition of protein synthesis (Mascarenhas et al., 2008). Up-regulation of Gnc4 only 
occurs in response to oxidative stress induced by hydrogen peroxide and provides 
specific resistance against hydroperoxides, thus would not be affected by 
accumulation of ROS seen in mutant SOD1 strains. This suggests that the up-regulated 
Gcn4 expression observed in SOD1 mutant strains must be due to amino acid 
starvation and not oxidative stress, since ROS-induced oxidative stress does not affect 
Gcn4 expression. From this, it can be deduced that SOD1 mutations lead to defects in 
amino acid biosynthesis. This evidence accompanied by the finding that SOD1 mutants 
demonstrate auxotrophy for multiple amino acids (Cherry et al., 2012) also supports 
the hypothesis that amino acid biosynthesis is disrupted in SOD1 mutant strains. 
GAAC integrates with the TOR pathway to facilitate nitrogen assimilation for synthesis 
of organic nitrogen compounds such as amino acids (Staschke et al., 2010), suggesting 
the TOR pathway may also be affected by SOD1 mutation. 
1.5.4 Mutant SOD1 disrupts TOR signalling 
Target of rapamycin (TOR) pathway is responsible for sensing nitrogen and nutrient 
availability within the cell and regulates transcription accordingly by transcription 
factors including Gln3. 
Mammalian TOR complex 1 (mTORC1) is an oligomer consisting of mTOR protein 
kinases in mammals. mTORC1 is regulated predominantly by Rheb, a ras-like GTPase, 
in its GTP-charged form known as Rheb-GTP. This regulation occurs through Rheb 
binding to mTOR which is essential for mTORC1 activation. The availability of nutrients, 
such as amino acids and particularly leucine in the cell determines Rheb-GTP’s ability 
to bind to mTOR; thus, nutrient availability indirectly regulates mTORC1 activation 
through Rheb-GTP. In turn, activated mTORC1 is responsible for controlling 
mammalian cell growth as appropriate. TOR signalling also exists in simpler eukaryotes 
such as yeast. 
Bastow (2013) discovered growth defects in S. cerevisiae expressing mutant Sod1p 
which could be rectified by addition of leucine to the growth medium. This is 
supported by the findings of Avruch et al. (2009) who discovered that the amino acid 
9 | P a g e  
 
regulation of TOR is a reversible process, most likely mediated by inhibition of Rheb-
GTP where amino acids are scarce, leading to no TOR activation and no cell growth, 
and removal of this inhibition upon readdition of amino acids, leading to TOR 
activation and cell growth. Avruch et al. (2009) also discovered that removal of 
different amino acids had varying effects on TORC1 signalling but that leucine or 
arginine starvation showed the greatest TORC1 down-regulation.  
The culmination of this evidence suggests that mutations in Sod1p may exert some 
interference on the integration of the GAAC and the TOR pathways in nitrogen 
assimilation which would account for the reduced amino acid biosynthesis observed in 
mutant-expressing cells. As a result of this, both GAAC and TOR pathways individually 
would be down-regulated due to this amino acid starvation, leading to defective cell 
growth. 
1.5.5 SOD1 and the vacuole 
The vacuole in yeast cells shows many similarities to the mammalian lysosome in 
terms of its function. Yeast vacuoles are an important storage compartment for amino 
acids and also provide an intracellular zinc pool which may be used for Sod1p 
maturation. Vacuolar zinc transport is mediated by vacuolar membrane protein Zrc1 
and to prevent zinc toxicity to the cell, zinc levels are regulated by Zap1 (Ellis et al., 
2004).   
Michaillat et al. (2012) showed that S. cerevisiae vacuole fusion and fragmentation 
were regulated by nutrient availability through TORC1. Under nutrient starved 
conditions when TORC1 is inactive, vacuolar fusion was increased producing a single 
large vacuolar compartment; this suggested that when vacuole-associated TORC1 is 
active, it is able to stimulate vacuolar fragmentation. Conversely, vacuolar 
fragmentation occurs under stress conditions such as osmotic stress caused by a 
hypertonic environment (Baars et al., 2007). Thus, the regulation of mTOR signalling is 
closely linked to vacuolar function. 
The vacuole also functions to degrade and recycle amino acids to facilitate protein 
synthesis. Evidence suggests mutant SOD1 expression may cause amino acid 
biosynthesis defects (Bastow, 2013), in addition to the finding that deletion of PEP4 
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from yeast SOD1 mutants resulted in growth defects. Pep4 protein in yeast is required 
for activation of vacuolar proteases that degrade proteins in the vacuole into their 
amino acid components, for use in protein synthesis (Jones, Zubenko, and Parker 
1982). Bastow (2013) concluded that mutant SOD1 may be exerting a toxic effect 
through accumulation in the vacuole or impairment of vacuolar functions. This finding, 
in addition to the implication of mutant SOD1 in TOR signalling disruption, suggests a 
potential role of mutant SOD1 in vacuolar amino acid transport in yeast. 
1.6 Modelling human neurodegenerative diseases 
Many varieties of model organism are regularly used in research of neurodegenerative 
diseases. These include animal models, ranging from rodents to worms, in addition to 
the modest yeast model.  
Arguably the most physiologically relevant, but not widely utilised, model in observing 
cellular effects of neurodegenerative diseases is human cells such as induced 
pluripotent stem cells (iPSCs). Spinal motor neurone neurofilaments, components of 
neuronal cell cytoskeletons, derived from iPSCs exhibit protein aggregate formation 
and neurite swelling when expressing mutant A4V and D90A SOD1 in early stages of 
the disease in this model (Chen et al., 2014). The same was also observed in human 
embryonic stem cell models expressing D90A mutant. Aggregates in these models 
resemble those seen in spinal cords of ALS patients, contributing to ALS research by 
showing that neurofilament aggregation occurs in early stages of ALS. 
Transgenic animal models, particularly rodents, are commonly used in 
neurodegenerative research; similarly to that observed in ALS patients, many animal 
models show neurofilament aggregation (Chen et al., 2014). Some SOD1 and ubiquitin 
aggregates in animal models present impaired axonal transportation causing muscle 
denervation and subsequent death of neuronal cell bodies. Rodent models 
recapitulate characteristic features of ALS such as axonal and mitochondria function, 
neuromuscular degeneration and death of motor neurones (Gurney et al., 1994) and 
more recently have indicated that over-expression of human wild type SOD1 can also 
cause symptoms of ALS including motor neuronal degeneration and reduced lifespan 
(McGoldrick et al., 2013). Animal SOD1 ALS models often also show aggregate 
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formation in mitochondria, particularly in the mitochondrial IMS, causing 
mitochondrial swelling and vacuolation (Gurney et al., 1994, Wong et al., 1995).  
Although non-human primate models are scarcely used in research due to ethical 
considerations, they can provide very useful insight into neurodegeneration. One non-
human primate model has been used to investigate effects of ALS-associated TDP-43. 
It was discovered that injection of TDP-43 into cervical spinal cords of monkeys via a 
viral vector caused progressive muscle weakness, atrophy and eventual paralysis 
around the site of injection (Uchida et al., 2012). At a later stage of disease 
progression, TDP-43 was shown to aggregate in the cytoplasm of motor neurones 
along with abnormal accumulation of phosphorylated neurofilaments, similar to that 
seen in ALS patients. 
Due to the ease of genetic manipulation and short lifespan of worms, C. elegans are 
now widely used in modelling protein misfolding disorders. In fact, the toxic 
mechanisms exhibited by non-coding mutations in worms show resemblance to those 
observed in mammalian cells (Therrien and Parker, 2014). Expression of human mutant 
SOD1 throughout the body of worms gives rise to impaired oxidative stress response 
and formation of protein aggregates (Oeda et al., 2011) in addition to disrupted 
neuronal transmission and movement defects (Wang et al., 2009). Similarly, pan 
neuronal human TDP-43 expression also leads to reduced worm motility and 
uncoordinated movement (Ash et al., 2010). Despite the differences that exist 
between mammals and worms, C. elegans ALS-associated neurodegeneration actually 
provides a good representation of the disease occurring in primate and rodent models.  
A model organism the most relatively different from human cells but by far one of the 
most widely used in research of human diseases is yeast. Despite their differences, the 
unicellular eukaryote S. cerevisiae retains many of the same basic functions as 
mammalian cells. One of the many contributions of yeast models to 
neurodegenerative research is the finding that mutant human SOD1 expression 
disrupts mitochondrial function and decreases electron transport, suggesting mutant 
SOD1 may impair assembly of the electron transport chain complex (Bastow et al., 
2011). In addition to this, protein misfolding and aggregation and well as many other 
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cellular dysfunctions can be monitored in yeast, representing human 
neurodegenerative diseases. 
1.7 Aims of the project 
Continuing from the findings obtained by Bastow (2013), this project intended to gain 
insight into a number of research questions: 
  
1. To investigate the toxicity of truncated SOD1 proteins in yeast as originally put 
forward by Ghadge et al. (2006) who discovered truncated SOD1 proteins to 
cause disease in chick embryo spinal cord neural cells.  Growth and viability of 
cells expressing various truncations of wild type SOD1 were measured to 
determine whether the truncations were toxic to yeast and whether protein 
length or GFP-tagging affected toxicity. 
2. To investigate the effect of toxic SOD1 on mitochondria and identify whether 
the gain-of-function demonstrated in toxic Sod1p targets mitochondria directly. 
Localisation of truncated SOD1 proteins in mitochondria was analysed in 
addition to analysis of mitochondrial function by testing the capability of yeast 
SOD1 mutants’ to respire. 
3. To elucidate the metabolic dysfunction observed in SOD1 mutants in relation 
to vacuolar amino acid transport.  
Growth analysis and viability of vacuolar amino acid transporter deletion 
strains expressing truncated SOD1 proteins were performed to investigate 
synthetic effects. Free amino acids concentrations in gene deletion strains were 
also analysed to determine whether gene deletion caused amino acid 
auxotrophies. 
4. To determine the effects of mutant SOD1 on C. elegans. 
Mutant SOD1 and wild type SOD1 were over-expressed in C. elegans to observe 
their toxic effects on the nervous system and organism as a whole. Lifespan and 
motility assays were used to assess their toxicity. 
 
 










Chapter 2  
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2.1 Growth media and conditions for Saccharomyces cerevisiae, 
Escherichia coli and Caenorhabditis elegans 
For all S. cerevisiae and E. coli solid media, 2% w/v granulated agar (Difco) was added 
to the media before autoclaving. Media were sterilised in a Prestige Medical bench-top 
autoclave at 121°C. 
S. cerevisiae and E. coli were grown on either solid or liquid media, with S. cerevisiae 
grown at 30°C and E. coli grown at 37°C. All liquid cultures subjected to continuous 
shaking at 200rpm. C. elegans were grown only on solid media, at 15°C, 20°C or 25°C as 
required.  
2.1.1 Yeast extract, peptone, dextrose (YEPD) medium for S. cerevisiae. 
2% w/v glucose, 1% w/v yeast extract, 2% w/v bactopeptone. 
2.1.2 Synthetic Complete (SC) drop-out medium for S. cerevisiae. 
2% w/v glucose, 0.67% w/v Yeast Nitrogen Base (Difco), 0.164% w/v synthetic 
complete leucine drop-out supplement (Formedium). 
Standard SC drop-out leucine medium. 
Yeast Nitrogen Base (YNB) contains ammonium sulphate and no amino acids; amino 
acid supplement was added as required. Leucine drop-out supplement (Formedium) 
contained all amino acids except leucine and was used for the selective growth of 
successfully transformed yeast cells expressing the LEU2 gene present on the plasmid. 
Low fluorescence SC double drop-out leucine and uracil medium. 
0.67% w/v low fluorescence Yeast Nitrogen Base (Formedium), 0.174% w/v synthetic 
complete leucine and uracil drop-out supplement (Formedium). 2% v/v sterile liquid 
glucose solution was added after autoclaving. 
Low fluorescence SC double drop-out leucine and uracil media was used for cultures 
prepared for fluorescence microscopy to provide the same nutrients as standard SC 
double drop-out leucine and uracil media, but gives a colourless solution which causes 
less interference during imaging. Sterile liquid glucose was added after autoclaving, 
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from a 40% glucose stock solution, to avoid caramelisation and darkening of the 
glucose during autoclaving. 
2% glycerol SC drop-out leucine medium. 
0.67% Yeast Nitrogen Base (Difco), 0.164% synthetic complete leucine drop-out 
supplement (Formedium), with 2% w/v (final) glycerol added after autoclaving. 
A solid version of this medium was used for mitochondrial function experiments of 
selectively grown transformed cells (Section 3.7.2) 
2.1.3 Luria Broth (LB) medium for E. coli. 
1% w/v bactotryptone, 0.5% w/v yeast extract, 1% w/v NaCl 
To select for E. coli successfully transformed with plasmids encoding the AmpR 
(ampicillin resistance) gene, 100µg/ml (final) of ampicillin was added to the media 
after autoclaving, from a 100mg/ml stock solution in water. The stock was kept at -
20°C. 
2.1.4 Nematode Growth Medium (NGM) for C. elegans. 
Standard NGM. 
0.3% w/v NaCl, 0.25% w/v bactopeptone, 1.7% w/v granulated agar. 
 
Distilled water was added up to the total volume then autoclaved. Following 
autoclaving, the liquid medium was cooled to 55°C in a water bath then sterile salt 
solutions added as follows: 
 
2.5% v/v KH2PO4 (pH6) 
0.1% v/v MgSO4 (1M) 
0.1% v/v CaCl2 (1M) 
0.1% v/v cholesterol (5mg/ml dissolved in ethanol) 
 
Salt solutions were added in the specified order to avoid a precipitate forming. 
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Amino acid-supplemented NGM.  
Leucine-supplemented solid NGM was made by adding varying volumes of sterile 
filtered 50mM leucine stock solution of L-leucine (Sigma) dissolved in sterile water. 
This was added to the medium after autoclaving, up to the total volume. Media was 
supplemented with 1 mM, 2mM or 5mM leucine. 
2.2 Strains 
2.2.1 S. cerevisiae strains. 
Yeast strains were obtained from the MATa Library, a gene deletion collection 
generated as part of the Saccharomyces Genome Deletion Project and were purchased 
from Open Biosystems. All strains were stored at -80°C.  
Table 2.1. Genotypes of yeast strains used in this study. 
Strain Genotype Collection 
BY4741 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 CWG424 
BY4741 ∆sod1 MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 sod1::HIS5 MFT 
BY4741 ∆avt1 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt1::KANMX MATa 
BY4741 ∆avt2 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt2::KANMX MATa 
BY4741 ∆avt3 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt3::KANMX MATa 
BY4741 ∆avt4 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt4::KANMX MATa 
BY4741 ∆avt5 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt5::KANMX MATa 
BY4741 ∆avt6 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt6::KANMX MATa 
BY4741 ∆avt7 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 avt7::KANMX MATa 
BY4741 ∆vba1 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 vba1::KANMX MATa 
BY4741 ∆vba2 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 vba2::KANMX MATa 
BY4741 ∆vba3 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 vba3::KANMX MATa 
BY4741 ∆vba4 MATα his3Δ 1 leu2Δ 0 lys2Δ 0 ura3Δ 0 vba4::KANMX MATa 
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2.2.2 E. coli strains. 
For amplifying plasmids by transformation and purification, α-select chemically 
competent E. coli cells with the genotype F- deoR endA1 recA1 relA1 gyrA96 
hsdR17(rk-, mk+) supE44 thi-1 phoA Δ(lacZYA-argF)U169 Φ80lacZΔM15 λ- were 
obtained from Bioline. 
 
For C. elegans culture and maintenance, E. coli strain OP50, a uracil auxotroph, was 
obtained from Dr. Jennifer Tullet (University of Kent). 
2.2.3 C. elegans strains. 
N2 wild type strains were obtained from Dr. Jennifer Tullet, University of Kent. 
Pnb-1::hSOD1-YFP and Pnb-1::hSOD1 G85R-YFP strains were created by Prof. Jiou 
Wang (John Hopkins Bloomberg School of Public Health), obtained through Prof. Alan 
Morgan (University of Liverpool). These strains contained integrated transgenes 
encoding human wild type SOD1 protein and the SOD1 G85R mutant protein, both C-
terminally fused to YPF. 
N2 strains were genetically out-crossed with the human SOD1 transgenic strains to 
standardize their genetic backgrounds (see Section 2.6.5) for use in future work. 
2.3 Plasmid use and analysis 
2.3.1 Plasmids. 
Table 2.2. Plasmids used in this study. 
Plasmid 
Name 
Backbone Insert Source 
pUKC 2801 pAG425 n/a Addgene 
pUKC 2809 pAG425 Yeast SOD1 E.Bastow 
pUKC 3216 pAG425 Yeast SOD1 fragment 1-36 E.Bastow 
pUKC 3217 pAG425 Yeast SOD1 fragment 1-49 E.Bastow 
pUKC 3218 pAG425 Yeast SOD1 fragment 1-84 E.Bastow 
pUKC 3219 pAG425 Yeast SOD1 fragment 1-115 E.Bastow 
pUKC 3220 pAG425 Yeast SOD1 fragment 1-125 E.Bastow 
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pUKC 3221 pAG425-EGFP  n/a Addgene 
pUKC 3222 pAG425-EGFP  Yeast SOD1 E.Bastow 
pUKC 3228 pAG425-EGFP  Yeast SOD1 fragment 1-36 E.Bastow 
pUKC 3229 pAG425-EGFP  Yeast SOD1 fragment 1-49 E.Bastow 
pUKC 3230 pAG425-EGFP  Yeast SOD1 fragment 1-84 E.Bastow 
pUKC 3231 pAG425-EGFP  Yeast SOD1 fragment 1-115 E.Bastow 
pUKC 3232 pAG425-EGFP  Yeast SOD1 fragment 1-125 E.Bastow 
B1468 pRS316 Cox4-RFP G. Wang 
 
All plasmids containing EGFP were N-terminally tagged. All pUKC plasmids contained 
the yeast LEU2 selectable marker, the GPD promoter, the 2µ plasmid origin of 
replication and ampicillin resistance gene AmpR as bacterial selectable marker. The 
B1468 Cox4-RFP plasmid was obtained from Dr. Geng Wang (Tsinghua University 
School of Life Science, China) and contained a URA3 yeast selectable marker. 
2.3.2 Transformation of S. cerevisiae. 
Initially, one colony of the yeast strain BY4741 was inoculated into 10ml YPD in a 
sterile 50 ml falcon tube and incubated at 30˚C with shaking at 200rpm overnight. The 
next day, 2ml of the culture was transferred to a sterile 2ml microcentrifuge tube and 
pelleted using a bench-top microcentrifuge at 13,000 rpm for 20 seconds. The 
supernatant was discarded and following were added to the cell pellet: 
240µl sterile 50% PEG-4000 
36µl 1M LiAc 
34µl sterile water 
2.5µl mercaptoethanol, 
10µl single stranded DNA (salmon sperm) 
4µl plasmid DNA (~1 g) 
 
 The mixture was vortexed for 1 minute to resuspend the cell pellet then incubated for 
30 minutes at 30˚C. The mixture was incubated for a further 30 minutes at 42˚C then 
cells were pelleted by microcentrifugation at 2000rpm for 5 minutes. For temperature 
sensitive strains, a 45 minute - 1 hour incubation at 30˚C was followed by 15 minutes 
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of incubation at 42˚C. After this time, the supernatant was discarded and the pellet 
resuspended in 150µl of sterile water and spread onto SC-leu solid media which were 
then incubated at 30˚C overnight in a static incubator. 
2.3.3 Transformation of E. coli. 
50µl of competent cells and 1µl of plasmid DNA (~ 1g DNA) were each thawed on ice 
before being mixed together in a 1ml microcentrifuge tube. The mixture was incubated 
on ice for 20 minutes then transferred to a water bath at 42˚C for 45 seconds. The 
mixture was incubated on ice for a further two minutes before adding 400µl of fresh 
LB medium. The LB-transformation mixture was incubated at 37˚C for 1 hour in a 
shaking incubator then 100µl was spread onto LB solid media containing ampicillin 
(100ug/ml) and incubated at 37˚C overnight in a static incubator. 
2.3.4 Plasmid purification from E. coli. 
Plasmids were isolated from E. coli grown overnight in LB medium with added 
ampicillin. Cells were harvested in a microcentrifuge at 8000rpm for 2 minutes and 
then plasmid DNA was isolated using the Thermoscientific GeneJET Plasmid Miniprep 
Kit K0503, according to Protocol A of the manufacturer. Centrifugation was carried out 
at 13,000rpm unless specified otherwise. Prior to use, RNase A was added to the 
resuspension buffer and ethanol added to the wash buffer, as specified in the protocol. 
As high copy plasmids were being isolated, no more than 5ml of bacterial culture was 
processed per GeneJET spin column. 
2.4 Protein analysis 
2.4.1 Native protein extraction.  
Native lysis buffer: 




1 protease inhibitor cocktail tablet (Roche) 
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60 OD units of overnight culture (yeast in stationary phase of growth) were harvested 
by centrifugation at 4000rpm for 5mins and 22°C. Harvested cells were then 
resuspended in 1ml of sterile ice cold water, transferred to a sterile 2ml Eppendorf 
tube and harvested in a Beckman benchtop centrifuge at 13000rpm for 15 seconds. 
The cells were then placed on ice. Supernatant was discarded and the cells 
resuspended in 400µl of ice cold native lysis buffer, centrifuged again as before and 
the supernatant discarded. Next, cells were resuspended in 200µl of native lysis buffer, 
whilst on ice, before adding 425-600µm acid-washed glass beads up to the meniscus. 
Cells were then lysed by vortexing for 1 minute followed by incubation on ice for 1 
minute. This was repeated five times. After lysing, cells were harvested at 13000rpm 
for 5 minutes, placed on ice, then the cell lysates extracted and transferred to pre-
chilled 2ml Eppendorf tubes. This was repeated to remove cell debris and the resulting 
native extracts were stored at 4°C for a few days prior to use. 
2.4.2 Bradford assay. 
To determine the concentration of protein in cell-free extracts, standards of known 
protein concentration were first prepared using bovine serum albumin (BSA) and 
concentrations of 100µg/ml, 250µg/ml, 500µg/ml, 750µg/ml, 1000µg/ml and 
1500µg/ml. The unknown concentration protein extracts were then diluted in water to 
1:4 ratio. To a cuvette containing 1.5ml of Bradford reagent, 50µl of protein sample 
(known standards and diluted unknown samples) was added, covered with parafilm, 
then inverted and left for 5-15 minutes to react. After this time, samples were 
measured in an Eppendorf BioPhotometer™ Plus at OD595 using a blank of Bradford 
reagent. Unknown protein concentrations were calculated by constructing a standard 
curve of protein concentration against absorbance at 595nm using the known BSA 
standards and plotting the unknown proteins. 
2.4.3 Protein separation by native PAGE and visualisation by SOD activity assay. 
The native protein extracts were diluted appropriately and 5X native sample buffer 
added in preparation for native PAGE.  
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5X native sample buffer: 
0.31M Tris pH 6.8 
0.05% v/v bromophenol blue 
50% v/v glycerol 
 
Native 12% polyacrylamide gels were made in plastic cassettes, first filling the cassette 
approximately ¾ full with resolving gel and covering with 100% ethanol to ensure even 
solidification. Once set, the ethanol was poured off and rinsed 2-3 times with distilled 
water before adding the stacking gel to the top of the cassette and placing an 
appropriate comb to form wells.  
 
Table 2.3. Composition of stacking and resolving gels for native PAGE. 
12% Stacking gel Resolving gel 
41.3% deionized water 60% deionized water 
33% acrylamide/bisacrylamide  (30% 
solution)   
14% acrylamide/biscrylamide  
(30% solution)  
25% 1.5M Tris-HCl pH8.8 25% 0.5M Tris-HCl pH6.8 
0.06% APS 0.05% APS 
0.13% TEMED 0.4% TEMED 
  
Native PAGE was run using 1x Tris-glycine native running buffer at 144 volts for 
approximately 1.5 hours, then the gel was stained in nitroblue tetrazolium (NBT) 
solution for 45 – 60 minutes on a shaker and shielded from light by covering the 
container with tin foil. 
NBT solution (double concentration): 
50% v/v KPO4 pH7.8 
0.2mg/ml w/v riboflavin 
0.265mg/ml w/v NBT (1 NBT tablet (Sigma) dissolved in 10ml water, to 1mg/ml 
concentration) 
0.2% v/v TEMED 
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After staining, the NBT solution was removed then the gel rinsed 2-3 times with dH2O 
and developed under a lamp in a small amount of dH2O. Development begun as soon 
as the gel was exposed to bright light, with the stained gel turning from yellow to dark 
blue in colour and with clear bands appearing where active SOD was present. Optimal 
signal was observable within the first hour after exposure but was usually left to 
develop overnight under the lamp. 
2.5 Analysis of S. cerevisiae  
2.5.1 Growth analysis. 
Colonies of yeast were inoculated into appropriate liquid media and grown overnight 
(as specified in section 2.1). The next day, the density of the cultures was determined 
by absorbance at OD600 in an Eppendorf Biophotometer™ Plus then cultures diluted to 
OD600 0.1 in 1ml of liquid media in a sterile 24-well microwell plate. Optical densities of 
the growing cultures were measured in a BMG LABTECH SPECTROstar Nano microwell 
plate reader with double-orbital shaking at 400rpm, with an excitation of 600 and 3 
flashes per well. Cycle time was 1800 seconds (30 minutes). 
After obtaining the absorbance data, growth analysis was done by calculating the log 
phase doubling time from the data using a Microsoft Excel template of semi-
logarithmic graphs plotting time in hours against OD600 absorbance values to 
determine the R-squared values and line equations of exponential trend lines, with the 
smallest R-squared value indicating fastest exponential growth. Doubling time (hours) 
was calculated by dividing ln2 by the x value of the line with the smallest R-value. 
The semi-logarithmic graph template used was created by Dr. Gemma Staniforth 
(University of Kent). 
2.5.2 Viability assays. 
Liquid cultures were prepared by inoculating colonies into SC drop-out leucine medium 
and incubating at 30°C shaking for 1-2 days as required. After this time, cultures were 
removed from the incubator and samples diluted by a factor of 1 in 80 in sterile 
distilled water in a 2ml Eppendorf tube.  
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100µl of the diluted culture was pipetted onto a haemocytometer next to the 
coverslip, next to the coverslip and the cell suspension drawn into the 
haemocytometer chamber by capillary action. Cells in each of the four large corner 
squares (each subdivided into 16 smaller squares – see Figure 2.1) of the grid were 
counted under a light microscope at 40X magnification. 
Figure 2.1: Diagram indicating four large corner squares of a haemocytometer used to count 
cells for a viability assay.  
The average number of cells in the four corner squares was calculated as follows: 
Average number of cells in corner squares x dilution factor (80) x 10,000 (standard for 
haemocytometer) = number of cells per ml of undiluted culture 
Serial dilutions were carried out, first diluting each sample to ~106 cells/ml in sterile 
water; next, diluting by 1/10 to give ~105 cells/ml, then again by 1/10 to give ~104 
cells/ml and lastly by diluting 2/10 to give ~2000 cells/ml (in total volume of 1ml). 
100µl aliquots of this final dilution, containing 200 cells, were spread on SC drop-out 
leucine agar plates and incubated at 30°C for approximately 5 days until colonies grew. 
Colonies were then counted using a manual or automated cell counter, each colony 
indicating one viable colony forming unit. Percentage viability was then calculated.  
2.5.3 Replica plating assays. 
The optical density of overnight cultures grown in SC drop-out leucine liquid medium 
were determined and diluted to OD600 1, 0.1, 0.001 and 0.0001 respectively in a 24-
well microwell plate by serial dilution. 5µl of the diluted cultures were placed in 
parallel spots on 2% glycerol SC drop-out leucine agar plates and left to dry for at least 
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10 minutes. Spotted plates were then incubated at 30°C in a static incubator for 3-4 
days. 
2.5.4 Fluorescence microscopy. 
Sample preparation.  
The optical density (OD600) of a yeast culture grown overnight in low fluorescence 
liquid medium (see Section 2.x) , was determined then diluted in the same liquid media 
to OD600 0.3 and grown for a further 3-4 hours in a shaking incubator until exponential 
growth phase was reached, identified by an OD600 between 0.6 and 0.8. 150µl of the 
log phase cells were pipetted onto a glass microscope slide and covered with a 
coverslip. A drop of immersion oil was then added to the coverslip prior to viewing. 
Microscope set-up and use. 
An Olympus IX81 motorised inverted research microscope with attached Hamamatsu 
Orca AG cooled CCD camera were used to acquire fluorescent images. An Olympus 
MT20 advanced fluorescence illumination system was used as the light source, using 1 
ms on/off time shutter speed setting. The Olympus cell^R imaging software was used 
to adjust camera settings and obtain and edit images. Cells were viewed at 100X 
magnification on the GFP-RFP setting and photographs captured on pixel size setting 
‘binning 1x1’.  
2.6 C. elegans preparation and analysis 
2.6.1 Bleaching. 
After obtaining the C. elegans Pnb-1::hSOD1-YFP and Pnb-1::hSOD1 G85R-YFP strains, 
the plates required cleaning before use. Firstly, 2ml of M9 buffer was added to plates 
of gravid adult worms, swirled to remove all worms from the surface of the plate and 
then transferred to a 1.5ml Eppendorf tube. Centrifugation of the suspension was 
performed to pellet the worms and the supernatant was carefully removed by 
pipetting. A 7:8 mixture of household bleach containing 5% sodium hypochlorite to 4M 
NaOH was added to the worm pellet and vortexed for 3-5 minutes to kill all hatched 
worms and contaminants. The NaOH and bleach solution should not be left on for 
more than 5 minutes for risk of killing the C. elegans eggs. After bleaching, the mixture 
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was centrifuged at 3000rpm to pellet the remaining eggs, then the pellet resuspended 
in 1ml M9 buffer. Centrifugation and resuspension was repeated twice more to wash 
off all bleach solution. The final suspension of eggs in M9 was pipetted onto a seeded 
NGM plate and incubated at 15-25°C. 
Stocks of clean, hatched worms were maintained in 50% osmotically-balanced M9 
buffer and 50% freezing buffer and stored at -80°C. 
Table 2.4: Compositions of M9 and freezing buffers. 
Freezing buffer:        M9 buffer: 
 0.59% w/v NaCl 0.3% w/v KH2PO4 
0.68% w/v KH2PO4 0.7% w/v Na2HPO4 
 30% v/v glycerol      0.5% w/v NaCl 




0.025% w/v MgSO4 
 
2.6.2 Lifespan assays. 
In preparation for the lifespan assay, NGM agar plates were seeded with 200µl of OP50 
strain of E. coli grown overnight at 37°C. These were used as the C. elegans food 
source. Once the bacteria had dried overnight, 200µl 5-fluoro-2'-deoxyuridine (FUDR) 
from a 100µM stock solution in water was inoculated on to the dried OP50 cells to give 
a final concentration of 10µM, and left to soak into the agar for at least 2 hours.  
Once the plates had fully dried, 20 L4 larval stage hermaphrodite worms were placed 
onto each plate, with 5 plates of 20 worms per strain to give a total of 100 specimens 
per strain. L4 stage hermaphrodites can be identified by the prominent crescent shape 
in their abdomen. This particular stage of worm is used in order to age synchronize the 
population used in the assay, thus day 1 of the assay begins on day 1 of adult life for all 
specimens. FUDR was used to inhibit hatching and growth of C. elegans progeny, to 
avoid counting of young worms that are not age synchronized. 
Throughout the assay, worms were observed every 2-3 days and scored on whether 
they were alive, dead or censored (lost or died of unnatural causes). Worms were 
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deemed to be dead if they did not move at all after being gently poked with a ‘worm 
pick’ composed of platinum wire attached to a glass pipette.   
2.6.3 Motility assays with leucine supplementation. 
First, leucine-supplemented NGM agar plates were prepared by seeding with cooled 
heat-killed OP50, killed by heating for 1 hour at 75°C in a water bath. Heat-killed 
bacteria were used to prevent metabolism of the supplemented amino acids by live 
bacteria. Once the bacterial cells were dry, 200µl 5-fluoro-2'-deoxyuridine (FUDR) from 
a 100µM stock was added to the plates and left to dry.  
In preparation for the assay, L4 stage worms were picked onto a clean NGM agar plate 
without bacteria and left for approximately 1 hour to remove the majority of live 
bacteria from their bodies and fully digest any consumed bacteria. After cleaning, 10 
L4 worms were placed onto 3 leucine-supplemented NGM plates for each strain and 
each concentration of leucine, giving 30 worms per strain per concentration. Worms 
were placed on control plates without leucine or experimental plates with leucine 
concentrations of 1mM, 2mM or 5mM and categorised and scored as either A, B or C 
every 2 days based on their motility. The scoring was determined by: 
A: Worm moves freely without touching it or moves freely when the plate is tapped. 
B: Worm moves freely once it is touched. 
C: Worm only moves slightly when touched (moves head or tail but cannot move 
freely). 
Worms were censored if they died during the assay or were lost on the plate. Any 
hatched progeny were removed from the plates and worms were transferred onto 
new plates if contamination occurred or there was live bacterial growth. 
2.6.4 Genetic out-crossing. 
In order to standardize the genetic backgrounds of the strains used, for valid 
comparisons to be made, male N2 worms from Dr. Jennifer Tullet (the same strain as 
the N2 hermaphrodites used in lifespan and motility assays) (T/T genotype) were bred 
with Psnb-1::SOD1 and Psnb-1::SOD1 G85R hermaphrodites obtained from Prof. Alan 
Morgan (University of Liverpool) (+/+ genotypes).  








Figure 2.2: Genotypes of C. elegans parents and progeny in genetic out-crosses. 
The success of breeding was monitored by the fluorescent phenotypes exhibited by 
the progeny; a successful cross would give approximately 50% +/T genotypes, 
consisting of half fluorescent worms and half not fluorescent, 25% +/+ genotypes in 
which all worms were fluorescent and 25% T/T genotype showing no fluorescence 
(table 2.5). 
Table 2.5: Genotypes of F2 generation genetically out-crossed C. elegans and corresponding 
fluorescent phenotypes. 











On a bacteria-free NGM agar plate, a small area of OP50 was spread onto the centre, 
with 6 N2 males and 3 hermaphrodites of either SOD1 wild type or SOD1 G85R mutant 
strains placed onto the bacteria. These worms were incubated at 15-25°C for around 3-
4 days to breed and progeny to grow. Once F1 generation progeny had reached L4 
stage, 5 L4 stage hermaphrodites were isolated onto a new OP50-seeded NGM plate 
and incubated for another 3-4 days to self-fertilize. When F2 generation progeny had 
grown to L4 stage, 15 L4 stage cloned hermaphrodites were separated onto one 
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seeded NGM plate per individual worm and incubated for another 3-4 days. After 
growth of sufficient progeny, the worms were screened using a Leica MZFLIII 
Fluorescence Stereomicroscope on GFP2 setting. Plates containing all fluorescent 
worms (T+/T+ genotype) were kept while those containing some (T+/T) or no 
fluorescent worms (T/T) were discarded. Breeding was repeated five more times each 
time using 3 hermaphrodites from the T+/T+ plates. After six full crosses, the out-
crossed worms stored at -80°C in a 1:1 solution of freezing buffer and M9 buffer (for 
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3.1 Introduction 
3.1.1 Using yeast as a model to study neurodegeneration. 
Yeast has been used extensively in modelling and understanding human diseases, 
neurodegenerative diseases. Although clear differences exist between yeast and 
complex higher eukaryotes like humans, basic processes including the cell cycle, 
intracellular transport and protein quality control systems are highly conserved 
between yeast and human cells. Disruption of protein quality control systems leads to 
mitochondrial defects, transcriptional deregulation and impaired trafficking in both 
species (Tenreiro and Outeiro, 2010); for example, neurodegenerative diseases 
Alzheimer’s and Parkinson’s are characterised by protein misfolding and formation of 
amyloidogenic aggregates, which is mirrored by yeast prion diseases that exhibit 
similar characteristics and biochemical properties.  Furthermore, cell death by 
apoptotic and non-apoptotic mechanisms is a process observed in neurodegenerative 
diseases, as a result of mitochondrial oxidative damage. This also appears to be 
conserved in yeast (Braun, 2012), which may undergo programmed cell death after 
sustaining oxidative damage in order to facilitate survival of the clonal population by 
decreasing nutrient usage (Cheng et al., 2008). It is suggested that approximately half 
of the genes involved in human heritable diseases also have homologues in yeast 
(Hartwell, 2004). 
A number of features observed in Parkinson’s disease can also be modelled in yeast; 
specifically, expression of heterologous α-synuclein inhibits yeast growth and over-
expression can cause cell death, characteristics also observed in higher eukaryotic 
models such as Drosophila, C. elegans and mice (Feany and Bender, 2000; Masliah et 
al., 2000, Lakso et al., 2003). Yeast has also been utilized in identifying therapeutic 
agents for α-synuclein toxicity by reducing formation of cytoplasmic aggregates, 
improving protein trafficking and reducing mitochondrial damage. These therapeutic 
agents were found to also reduce α-synuclein induced toxicity in C. elegans and rat 
neuronal midbrain cultures (Su et al., 2010).   
In addition, similarities are shown between yeast and transgenic mouse models of 
Huntington’s disease, particularly in relation to the regulation of polyQ expression and 
toxicity by the kynurenine pathway (Campesan et al., 2011; Giorgini et al., 2008; 
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Zwilling et al., 2011). Murine and mammalian cell models expressing Huntington’s 
Disease-associated huntingtin protein also showed traits of mitochondrial dysfunction 
and oxidative stress reproduced in yeast models (Bossy-Wetzel et al., 2008; Ross and 
Tabrizi, 2011; Correia et al., 2012). 
3.1.2 Yeast as a model to study the role of SOD1 in ALS. 
Yeast models have also been used in understanding the mechanisms by which mutant 
SOD1 causes toxicity in diseases such as familial ALS. Growing evidence suggests that 
SOD1, despite being a primarily cytosolic protein, is essential in regulating 
mitochondrial function and preventing oxidative damage. Sturtz and Culotta (2001) 
reported that ∆sod1 strains of S. cerevisiae exhibited metabolic defects including 
defective methionine and lysine biosynthesis when grown aerobically in media 
containing glucose; they also reported rapid death of stationary phase that correlated 
with increased production of reactive oxygen species, while other evidence shows an 
increase in protein carbonyls in ∆sod1 cells, products of metal-catalyzed oxidation 
indicative of oxidative stress even in the presence of mitochondrial SOD2 (Weisiger 
and Fridovich, 1973). Investigation into the role of anti-apoptotic mitochondrial 
protein, Bcl-2, in SOD1-mediated toxicity also showed Bcl-2 expression in a ∆sod1 
strain of S. cerevisiae to improve survival of stationary phase cells by providing an 
antioxidant and anti-apoptotic role (Longo et al., 1997). Pedrini et al. (2010) indicated 
that fALS-associated SOD1 mutants interact with Bcl-2, causing a toxic effect in mice 
and human spinal cord cells.  
However, Nishida et al. (1994) studied mutations in yeast SOD1 that correspond to the 
human disease-causing mutants, showing defects in metal incorporation and 
enzymatic activity, suggesting fALS was not solely caused by oxidative damage. Further 
research has found that expression of yeast SOD1 encoding ALS-associated mutations 
leads to increased mitochondrial respiration in addition to increased amino acid 
biosynthesis and trehalose biosynthesis, which are linked to leucine signalling, 
portraying a potential effect of mutant SOD1 on amino acid signalling (Bastow, 2013). 
3.1.3 Truncated wild type SOD1 proteins in neural death. 
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Zu et al. (1997) reported that some fALS genotypes show truncations in exon 5 of wild 
type SOD1 encoding amino acids 119 to 153 at the carboxyl end of the human SOD1 
protein. One such truncation, L126Z, is caused by a substitution resulting in a stop 
codon at amino acid residue 126 of the protein (Zu et al. 1997); while another, FS126, 
has two base pairs deleted leading to a frameshift and stops translation at residue 131 
(Pramatarova et al. 1994). These truncated SOD1 proteins have shown a tendency to 
form aggregates in human embryonic kidney cells (Wang et al. 2003).   
Ghadge et al. (2006) first investigated truncated SOD1-mediated toxicity. When 
expressing wild type SOD1-YFP in chick embryo spinal cord cells, it was discovered that 
the protein was distributed throughout the cells’ cytoplasm, whereas mutant A4V 
SOD1-YFP formed intracellular aggregates and caused apoptosis. However, when 
truncated 1-125 amino acid SOD1-YFP was electroporated and expressed in the same 
cell type, cells exhibited aggregate formation and showed increased DNA 
fragmentation indicative of apoptotic signalling cascades (shown by TUNEL assays) 
compared to wild type SOD1-YFP expression. Further truncated SOD1-YFP proteins 36, 
49, 84 and 115 amino acids in length (truncated from the carboxyl end) were also 
electroporated and expressed in chick embryo spinal cord neural cells and showed 
aggregate formation and signs of apoptotic signalling by TUNEL. Further to this, to 
mimic the genotype of individuals carrying one mutant SOD1 allele and one normal 
SOD1 allele, truncated 1-36 amino acid SOD1 was co-electroporated with wild type 
SOD1; this still showed a significant increase in apoptosis compared to wild type SOD1, 
even in the presence of functional Sod1p, indicating a toxic gain of function in the 
truncated Sod1p. 
In this chapter, the effects of expressing truncated wild type SOD1 proteins in baker’s 
yeast, S. cerevisiae, will be investigated and the mechanisms by which they cause 
toxicity will be explored.  
3.2 Expression of truncated SOD1 proteins causes defective cell growth 
Growth analyses are a useful tool in investigating the effects of genetic or epigenetic 
changes on the growth rate and viability of cells. When grown at optimal conditions of 
30°C in rich media such as YPD, S. cerevisiae have a doubling time of approximately 1.5 
hours, however they are sensitive to nutritional deprivation, thus growth in minimal 
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media increases doubling time to around 2 hours. Changes in growth pattern or 
doubling time can be an indicator of impairment or enhancement of cellular function 
as a result of genetic manipulation or response to stress. Growth of cells following 
gene deletion is commonly used as a method of assessing the importance of a gene 
under changing growth conditions. 
 
Figure 3.1: Truncated wild type yeast SOD1 proteins. Truncated proteins were created by site-
directed mutagenesis and insertion of a stop codon leading to production of truncated SOD1 
proteins 36, 49, 84, 115 and 125 amino acids in length (Bastow, 2013). Image adapted from 
(Bastow, 2013). 
For these experiments, S. cerevisiae SOD1 deletion strains were a transformed with 
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 Figure 3.2: Expression of truncated SOD1 proteins causes defective growth in yeast. The five 
truncated isoforms of Sod1p, Sod1p1-36, Sod1p1-49, Sod1p1-84, Sod1p1-115 and Sod1p1-125were 
expressed in a ∆sod1 strain. Cells were grown for 48 hours in SC-leu media at 30°C. The three 
growth curves a), b), and c) represent three biological repeats of this experiment.  
 
Figure 3.3:  Sod1p1-84 and Sod1p1-125 protein fragments are most toxic to cells. The three 
biological repeats of growth data were used to calculate an average doubling time for each 
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proteins gave a doubling time equal to that of the wild type control suggesting they are 
not fully functional, although Sod1p1-36, Sod1p1-49 and Sod1p1-115 truncations grew 
marginally better than the Δsod1 control expressing no SOD1. Sod1p1 -84 and Sod1p1-125 
truncations grew slower than the negative control. 
 The growth curves (Figure 3.2) created from plotting the obtained data on a 
logarithmic scale indicated that the ∆sod1 positive control expressing full-length 
ySOD1 was able to reach the same final OD600 as the BY4741 positive control 
expressing the empty plasmid, with no significant decrease in growth rate. However 
the ∆sod1 negative control expressing no Sod1p, along with all five Sod1p truncations, 
reached a lower final OD600 than the positive controls; while the two positive controls 
also show a slight growth increase after diauxic shift occurs, the growth of cells 
expressing truncated proteins or negative control plateaus soon after diauxic shift, 
indicating these cells may be less able to metabolise non-fermentable carbon sources.  
Exponential phase growth also appears to be slowed in cells expressing Sod1p1-84 
protein fragment in two of three growth curve repeats whereas Sod1p1-125 fragments 
appears slowed in all three. This is reflected in the average doubling times (Figure 3.3), 
where the two fragments have the slowest doubling times, indicating they may be 
toxic to cells. To determine whether the differences observed in doubling times were 





Δsod1 control 0.012 - 
Δsod1 ySOD1 0.974 0.018 
BY4741 control - 0.012 
Sod1p 1-36 0.035 0.140 
Sod1p 1-49 0.060 0.080 
Sod1p 1-84 0.097 0.432 
Sod1p 1-115 0.086 0.146 
Sod1p 1-125 0.003 0.032 
 
Figure 3.4: T-tests indicating significance of differences in doubling time between truncated 
SOD1 proteins and controls. T-tests performed using a two-tailed hypothesis and a critical P-
value of 0.05 to test whether there was a significant difference in doubling time between cells 
expressing each truncated SOD1 protein against either a positive (BY4741 strain) or negative 
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(∆sod1 strain) control. P-values >0.05 are deemed insignificantly different and those <0.05 
indicate significance and are highlighted yellow. 
In a two-tailed t-test with a P-value of 0.05, the BY4741 control was significantly 
different to the ∆sod1 control but not ∆sod1 ySOD1, as expected. Similarly, the ∆sod1 
control was significantly different to both positive controls. The t-test indicates that of 
the truncated proteins tested, only Sod1p1-36 and Sod1p1-125 have growth rates 
significantly different to the BY4741 control whereas only Sod1p1-125 is significantly 
different to the ∆sod1 control. However, an important observation is that the third 
biological repeat conducted for Sod1p1-84 appeared anomalous compared to the 
results of the first two repeats. The doubling time for repeats 1 and 2 were 2.72 and 
2.65 hours but for repeat 3, was 3.2 hours. When including all three results in the t-
test, this gave a P-value of 0.097, which indicates insignificant difference to the 
control, despite Sod1p1-36 having a mean doubling time closer to that of the control 
and being shown significant in the t-test; since the t-test also takes variability in the 
dataset into account when calculating a significance value, the presence of this 
anomaly likely affected the t-test and inaccurately calculated the significance value. In 
order to accurately calculate the significance, further repeats would need to be done 
to allow exclusion of the anomaly. Nevertheless, it can be concluded that Sod1p1-36 
may exhibit toxicity that slows cell growth somewhat, but cells still grow faster than 
when SOD1 is deleted. Sod1p1-125 is the only truncated protein shown to be 
significantly different, and in this case slower, than both positive and negative controls, 
so it can be concluded that Sod1p1-125 protein fragment is actively exhibiting a toxic 
effect.    
3.3 SOD1 truncation leads to loss of enzymatic activity 
To determine whether the Sod1p1-36, Sod1p1-49 and Sod1p1-115 truncated proteins 
identified as non-toxic in growth experiments were providing any enzymatic 
functionality, native protein extracts isolated from overnight yeast cultures were 
diluted appropriately with native sample buffer then loaded into a 12% polyacrylamide 
gel and separated by native PAGE for approximately 1.5 hours. The gel was then 
stained with nitroblue tetrazolium (NBT) chloride solution and developed under a 
bright light. NBT is a photogenic substrate and when exposed to bright light, changes 
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the stained gel from yellow to dark blue/purple in colour. This process relies on the 
reactivity of the solution components riboflavin and TEMED, which form superoxide 
radicals upon light exposure. The reduction of NBT by superoxide radicals forms a blue-
coloured product however active SOD1 enzyme breaks down the superoxide radicals 
and competitively inhibits NBT reduction, causing a clear band to form where active 
SOD1 is present. 
 The activity assay (Figure 3.5) shows no detoxification of superoxide radicals by any of 
the truncated SOD1 proteins indicating none of them possess enzymatic activity, due 
to the lack of signal for Sod1p in any of the lanes containing Sod1p fragments. This 
suggests that Sod1p1-36, Sod1p1-49 and Sod1p1-115 truncated proteins are not active nor 
are they toxic under these conditions, whereas Sod1p1-84 and Sod1p1-125 truncations 
are also enzymatically inactive but have some acquired toxicity. The mechanism of this 
toxicity will be investigated in later sections. 
 
Figure 3.5: Truncated SOD1 proteins are unable to detoxify superoxide radicals produced in 
an NBT assay. Native proteins with native sample buffer added were loaded onto the 
polyacrylamide gel and assessed for SOD1 activity as described in Materials and Methods 
2.4.3. Native proteins were loaded onto the gel at between 1000-3000ug/ml concentrations as 
determined by Bradford assays, to ensure a strong signal was produced. The top row of clear 
bands indicates Sod2p, which shows clear bands in the controls but weak bands in cells 
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expressing truncated SOD1 proteins. The lower row of bands indicates active SOD1, and is only 
seen in the two positive controls. 
3.4 Enzymatic activity of truncated SOD1-GFP fusion proteins 
For the purpose of visualisation by fluorescence microscopy, cells were transformed 
with plasmids expressing N-terminal GFP tagged versions of the truncated SOD1 
proteins made by Bastow (2013). Stevens and Chia (2010) found that tagging Sod1p 
with GFP may affect its enzymatic activity; when comparing GFP-tagged G93A human 
SOD1 mutant with its untagged version, the GFP-tagged version showed a 65% 
reduction in activity; however, no difference in their dimerization states was observed. 
To maintain the validity of the experiments using these GFP fusion proteins, cells 
expressing truncated SOD1-GFP fusion proteins were analysed. 
3.4.1 GFP fusion to Sod1p1-115 truncation increases its toxicity.  
A S. cerevisiae SOD1 deletion strain containing pAG425-EGFP plasmids encoding the 
truncated SOD1 proteins and controls were grown overnight in 5ml SC-leu liquid 
medium, then cultures diluted the next day to OD600 0.1 in the same media in a 24-well 
microwell plate and their growth recorded. Surprisingly, it was discovered that the 
doubling time of Sod1p1-115-GFP protein has greatly increased (Figure 3.6b), inferring a 
strong toxic effect acquired as a result of fusing GFP to this protein fragment. On the 
contrary, the doubling time of Sod1p1-125-GFP fragment compared to its non GFP-
tagged counterpart is reduced to the extent that it appears to exceed the rate of the 
wild type control, indicating GFP fusion may have reduced or eliminated the toxicity of 
this protein fragment. Statistical analysis was performed to determine whether these 
differences could be deemed significant.  




Figure 3.6: GFP fusion affects the growth of cells expressing truncated SOD1 proteins in a 
∆sod1 strain. a) Growth analysis shows cells expressing Sod1p1-115-GFP fusion protein to have a 
significantly slowed exponential phase growth rate compared to all other fragments and 
controls, and reaching a lower final OD600. b) The doubling time of cells expressing Sod1p
1-115-
GFP fusion protein is significantly greater than other fragments, suggesting a toxic effect on 
cells. Conversely, the doubling time of cells expressing Sod1p1-125-GFP is comparable to the 
controls, being the only experimental strain with a doubling time of < 3hrs. Doubling times 
were calculated from an average of three biological repeats, error bars indicating variability 
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Δsod1 control-GFP 0.17 - 
BY4741 control-GFP - 0.17 
Sod1p 1-36 -GFP 0.03 0.048 
 Sod1p 1-49 –GFP 0.23 0.44 
Sod1p 1-84 –GFP 0.03 0.10 
Sod1p 1-115 –GFP 0.03 0.03 
Sod1p 1-125-GFP 0.04 0.02 
 
Figure 3.7: T-tests indicating significance of differences in doubling time between truncated 
SOD1-GFP fusion proteins and controls. T-tests performed using a two-tailed hypothesis and a 
p value of 0.05 to test whether there was a significant difference in doubling time between 
cells expressing each truncated SOD1-GFP fusion protein against either a positive (BY4741 
strain) or negative (∆sod1 strain) control. T-test values >0.05 are deemed insignificantly 
different and those <0.05 indicate significance. Values highlighted in yellow indicate 
significance. 
To determine whether differences in doubling time were significant, t-tests were 
performed. Analysis showed that compared to the BY4741 wild type control, doubling 
times of cells expressing all truncated proteins except Sod1p1-49-GFP differ significantly. 
However, only Sod1p1-115-GFP and Sod1p1-125-GFP differ significantly from the ∆sod1 
control, implying any difference caused by expressing GFP-fused Sod1p1-36 or Sod1p1-84 
are not due to acquired toxicity any more than simply deleting the functional SOD1 
gene. By looking at the mean doubling times of the three repeats (Figure 3.6b), it can 
be confirmed that expression of Sod1p1-115-GFP significantly slows cell growth 
indicating a strong toxic effect, and also confirmed the growth rate of Sod1p1-125-GFP 
significantly increases growth rate even compared to the wild type protein, leading to 
the hypothesis that GFP fusion may have provided structural stability to the truncated 
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3.4.2 GFP fusion allows Sod1p1-125 truncation to form a functional dimer. 
The growth analysis of truncated SOD1-GFP fusion proteins suggested that GFP-tagging 
of truncated SOD1 proteins may affect their enzymatic activity. Native protein extracts 
were prepared from these strains and examined for SOD activity as described in 
Materials and Methods 2.4.3.  
 
Figure 3.8: Truncated Sod1p1-125 fused to GFP shows enzymatic functionality in an NBT assay. 
Native proteins were diluted to 1200µg/ml in water and appropriate volume of native sample 
buffer for loading onto a 10% polyacrylamide gel. The top row of clear bands indicates Sod2p 
clearly present in all samples. The lower row of bands indicates active SOD1, and is seen not 
only in the two positive controls but also very prominently in the Sod1p1-125-GFP sample. 
Contrary to the NBT assay of truncated SOD1 protein without GFP fusion, which 
showed none of the truncated proteins to have enzymatic activity, GFP fusion to 
Sod1p1-125 appears to restore its function to that of full-length Sod1p; this suggests that 
similar to the findings of Stevens and Chia (2010), GFP fusion did indeed alter the 
activity of the truncated Sod1p1-125 enzyme, perhaps by altering its stability or to ability 
dimerize. This may indicate that Sod1p1-125 retains some structural component that the 
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other protein fragments do not due to their truncation, or that Sod1p1-125 is the only 
truncation long enough in length to form a stable protein.  
3.5 Viability is largely unaffected by expression of truncated SOD1 
proteins 
Viability was determined by calculating the number of cells in an overnight culture 
then diluting the cultures by serial dilution and finally spreading a known number of 
colony forming units onto solid SC-leu media. Colony growth was counted, with one 
colony indicating one viable colony forming unit, and percentage viability was 
calculated. Assessing cell viability can highlight incidences of premature cell death or 
senescence within the culture. 
Truncated SOD1 proteins were expressed in a ∆sod1 strain in order to investigate 
whether they reduced viability after 24 hours of growth in SC-leu media.
 
Figure 3.9: Average viability of cells expressing truncated yeast SOD1 is largely unaffected by 
protein fragment length in a ∆sod1 strain. Representative of an average of two biological 
repeats of the same experiment, each an average of 3-4 technical repeats. Error bars represent 
variability between biological repeats. Viability of controls particularly ∆sod1 ySOD1 appears 
very variable between biological repeats but was less so between technical repeats. In all three 
repeats, the longest Sod1p fragments, Sod1p1-115 and Sod1p1-125, give the lowest viability of all 
fragments but do not show significant reduction compared to the BY4741 control, which 
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Although there was some visible pattern in viability of cells expressing Sod1p 
fragments, with longer fragments Sod1p1-115 and Sod1p1-125 showing the lowest 
percentage viability in all experiments performed, the significance of differences in 
viability between fragments are difficult to assess due to the variability of controls, 
where the differences in viability between fragments were generally 20-25% in all 
experiments, whilst the ySOD1 control varied up to around 20% between experiments. 
Statistical analysis by means of t-testing showed the differences in viability between 
cells expressing truncated SOD1 proteins and the negative control were not significant; 
the conclusion from this data is that the differences observed in viability when 
expressing truncated SOD1 proteins are due to natural variability rather than a 
significant life-reducing effect exerted by the Sod1p fragments.  
3.6 Role of mitochondria in SOD1-mediated toxicity 
Association with mitochondria has been strongly linked to mutant SOD1-mediated 
toxicity especially in ALS disease states. A significant body of evidence shows that high 
levels of mutant SOD1 are present in spinal cords of transgenic ALS mice (Jonsson et 
al., 2006; Karch et al., 2009; Zetterström et al., 2013) while Wong et al. (1995) showed 
that expression of SOD1 mutants lead to mitochondrial abnormalities. Further studies 
in motor neuronal cell lines found that expression of mutant SOD1 in the IMS leads to 
formation of insoluble oligomers inside mitochondria, resulting in toxicity and cell 
death (Cozzolino et al., 2009; Magrané et al., 2009). Most previous research has 
hypothesised that mitochondrial toxicity by mutant SOD1 is caused by accumulation of 
these insoluble protein aggregates, with multiple mouse models showing correlation 
between occurrence of insoluble mutant SOD1 aggregates and manifestation of ALS 
symptoms (Johnston et al., 2000; Wang et al., 2002). In the following experiments, 
truncated SOD1 proteins were expressed in yeast to investigate their localisation. 
Fluorescence microscopy was used to determine whether truncated SOD1 proteins 
localised to the mitochondria of S. cerevisiae, by fusing the Sod1p fragments to green 
fluorescent protein (GFP) and expressing them in yeast along with red fluorescent 
protein (RFP) fused to mitochondrial inner membrane protein, Cox4. Cultures were 
grown overnight in low fluorescence media were diluted the next day to OD600 0.3 in 
the same media then grown for a further 3-4 hours to reach exponential phase before 
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observation using a fluorescence microscope with beamsplitter attached. A 
beamsplitter allows two paths of light at different wavelengths to be directed at the 
sample, illuminating GFP and RFP simultaneously. The captured images are then 
overlaid to observe co-localisation (Figure 3.11). 
 
Figure 3.10: Incidence of co-localisation of truncated Sod1p with mitochondria. Co-
expression of GFP-fused truncated SOD1 proteins along with Cox4-RFP fusion protein 
was used to identify mitochondrial localisation a) in a SOD1 deletion strain and b) in a 
wild type BY4741 strain. One hundred cells were observed for each sample and cells 
scored positively for co-localisation if there was any GFP and RFP co-localisation within 
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Figure 3.11: GFP and RFP localisation and co-localisation. Images taken from an 
exponential phase sample of ∆sod1 strain expressing truncated Sod1p1-36-GFP fusion 
protein with Cox4-RFP showing a) Sod1p1-36-GFP localisation b) Cox4-RFP 
mitochondrial localisation and c) visualisation of both fluorescent proteins using a 
beamsplitter. 
Co-localisation of GFP-tagged truncated SOD1 proteins with Cox4-RFP in the wild type 
strain was found  to be significantly higher in the positive control expressing full-length 
Sod1p than in cells expressing any of the truncated SOD1-GFP proteins (Figure 3.10b) 
with the exception of  Sod1p1-36 in which 50% of cells showed mitochondrial 
localisation; This finding was not reproduced when Sod1p1-36  was expressed in a  SOD1 
deletion strain (Figure 3.10a) where ySOD1 still showed approximately the same 
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3.7 Effects of vacuolar amino acid transporter deletion 
Earlier in this chapter, it was shown that expression of toxic Sod1p fragments in a 
SOD1 deletion strain caused cell growth to slow but did not reduce viability. Evidence 
supporting this study (Bastow, 2013) suggests that mutations in SOD1 may lead to 
metabolic defects that can result in amino acid auxotrophy. 
The yeast vacuole acts as a storage compartment for amino acids where they remain 
inert, until they are transported to the cytosolic amino acid pool when required for 
metabolism and protein synthesis (Sekito et al., 2008). The majority of the vacuolar 
amino acid pool consists of basic and neutral amino acids whereas acidic amino acids 
glutamate and aspartate are almost solely localised to the cytosolic pool. AVT and VBA 
are two types of vacuolar amino acid transporters existing in yeast. Most of these 
transporters, including AVT and VBA classes, actively transport amino acids across the 
membrane by utilizing a proton electrochemical gradient generated by Vacuolar-type 
H+-ATPase (V-ATPase) enzyme (Nelson et al., 2000). AVT transporters are all members 
of the amino acid/auxin permease family and are related to neuronal vesicular GABA-
glycine transporters found in higher eukaryotes, and have known orthologues in 
plants, invertebrates like C. elegans as well as mammals such as rats and mice (Sekito 
et al., 2008; Young et al., 1999). While VBA transporters belong to the major facilitator 
superfamily (MFS), a large group of membrane transporters found ubiquitously in 
prokaryotes and eukaryotes (Pao et al., 1998; Shimazu et al., 2005; Sekito et al., 2008).  
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Figure 3.12: Roles of yeast AVT and VBA amino acid transporter and phenotypes of null 
mutants. Ubiquitous vacuolar transporters involved in influx and efflux of amino acids. The 
majority of null mutants show abnormal vacuolar morphology and reduced competitive 
fitness, while some also show decreased stress resistance and tolerance to drugs such as 
caffeine and cyclohexamide. + indicates an increase in a characteristic while – indicates a 
decrease. 
Emerging evidence has implicated a link between mutant SOD1 and the yeast vacuole. 
Corson et al. (1999) found that SOD1 deletion caused a significant increase in vacuolar 
fragmentation, whereas Wong et al. (1995) and Bastow (2013) showed mutant SOD1 
expression also led to increased vacuole formation. Deletion of SOD1 results in amino 
acid auxotrophies, indicating a role of SOD1 in metabolic function. (Chang and Kosman, 
1990; Kwon, Jeong, and Roe, 2006; Cozzolino et al., 2009). In this section, the potential 
interaction between Sod1p and vacuolar amino acid transport will be explored by 
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3.7.1 Expressing truncated SOD1 causes growth defects in some vacuolar amino acid 
transporter deletion strains. 
To examine whether there was an interaction between truncated Sod1p and any of the 
vacuolar amino acid transporters, AVT and VBA amino acid transporter deletion strains 
were transformed with a plasmid encoding the truncated SOD1 protein that proved 
most toxic to cells in earlier Chapter 3, the Sod1p1-115-GFP fusion protein. Their growth 
was analysed and doubling times calculated and compared to those of the deletion 
strains expressing the control pAG425-EGFP plasmid. 
 
Figure 3.13: Growth is slowed by expression of Sod1p1-115-GFP fusion protein in vacuolar 
amino acid transporter deletion strains. Percentage difference in doubling time (Dt) indicates 
the increase or decrease in doubling time when expressing Sod1p1-115-GFP fusion protein 
compared to the control expressing only GFP. Average % difference gives an average of 
doubling time differences between the two biological repeats. A positive figure indicates 
growth being slowed by expression of Sod1p1-115 –GFP compared to the control whereas a 
negative figure indicates a growth increase. Those with an average doubling time increase of 
>20% are highlighted in yellow and those with an increase of >5% in orange. Strains with an 
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increase in doubling time when expressing Sod1p1-115 -GFP were deemed to be affected by its 
toxicity. BY4741 control data are from one repeat only. 
Growth analysis showed that deletion of AVT3, AVT4, AVT5, AVT6 and VBA1 did not 
exhibit a synthetic effect with the truncated Sod1p1-115-GFP fusion protein when 
compared to the GFP control (Figure 3.13). However a synthetic interaction was 
observed in strains lacking AVT1, AVT2, AVT7, VBA2, VBA3, VBA4 or VBA5 in at least 
one of the experiments (Figure 3.12, Repeat 2) The most prominent and reproducible 
effects were observed in cells lacking AVT2, VBA3 or  VBA4 which all showed a >20% 
decrease in growth when expressing Sod1p1-115-GFP.  
3.7.2 Investigation of a synthetic effect by truncated SOD1 proteins on mitochondrial 
and vacuolar function. 
Further investigation into the impact of truncated Sod1p expression on mitochondria 
looked at their effects on mitochondrial function rather than physical aggregate 
formation, this time in vacuolar amino acid transporter deletion strains. When 
investigating polyQ aggregation in disease, Solans et al. (2006) reported decreased 
mitochondrial respiration and an increase in ROS production, as a result of aggregate 
formation. Ferri et al. (2010) also suggested that toxicity of mutant SOD1 is a result of 
mitochondrial dysfunction but not by aggregate formation, since solubilisation of 
mutant Sod1p outside the mitochondrial matrix of human motor neurones by over-
expression of glutaredoxin did not prevent mitochondrial toxicity; whereas 
glutaredoxin expression inside the mitochondrial matrix was able to inhibit 
mitochondrial dysfunction by restoring the correct redox environment. Results 3.2 also 
indicated that ∆sod1 cells expressing Sod1p fragments may have a slight defect in non-
fermentable metabolism as growth analyses showed growth appeared to plateau after 
diauxic shift. 
To determine whether truncated  SOD1 proteins cause mitochondrial dysfunction and 
indeed hindering the cells’ ability to grow post-diauxic shift, they were expressed in 
yeast strains with deleted vacuolar amino acid transporter genes and grown on media 
containing non-fermentable carbon source glycerol instead of fermentable source 
glucose.  
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Figure 3.14: Amino acid transporter deletion strains expressing truncated and mutant SOD1 
are able to grow on non-fermentable carbon sources. From left to right (for each image): 5µl 
spot of culture with an OD600 of 1, measured in an Eppendorf Biophotometer™ Plus; spot with 
OD600 of 0.1; spot with OD600 of 0.01; spot with OD600 of 0.001, achieved by serial dilution. 
Controls in figures a) and c) contain empty pAG425 backbones while controls in b) contain 
pAG425-EGFP backbones.  
All vacuolar amino acid transporter strains expressing either fALS-associated SOD1 
mutants or toxic truncated proteins retained the ability to grow in the absence of 
glucose, reflecting their functional respiratory metabolism and suggesting oxidative 
phosphorylation defects are not part of the toxic mechanism exerted by these 
proteins. 
These results did not elucidate any novel insight into the mechanism by which toxic 
Sod1p fragments or mutants may be causing mitochondrial dysfunction, so the focus 
of the next experiments explored alternative cellular targets for SOD1-mediated 
toxicity. Since it is thought that toxic SOD1 protein likely affect multiple cellular targets 
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to cause cell death and their mechanism has been notoriously difficult to elucidate, the 
role of mitochondria in SOD1-mediated toxicity has not been ruled out. 
3.7.3 Effects of truncated SOD1 expression on the viability of vacuolar amino acid 
transporter deletion strains.  
Vacuolar amino acid transporter deletion strains that exhibited a toxic effect as a result 
of Sod1p1-115-GFP expression were also transformed with a plasmid expression 
different truncated SOD1 protein, non-GFP fused Sod1p1-125. AVT1, AVT2, AVT7, VBA2, 
VBA4 and VBA5 deletion strains expressing either Sod1p1-115-GFP, Sod1p1-125 or a GFP 
only control plasmid were grown for 48 hours in SC-leu media, along with a wild type 
control, and assessed for culture viability. 
Figure 3.15: Viability of vacuolar amino acid transporter deletion strains expressing toxic 
SOD1 truncations are reduced compared to wild type control. Deletion strains expressing 
truncated SOD1 proteins were grown for 48 hours in SC-leu media then their percentage 
viability calculated according to Materials and Methods 2.5.2. Data representative of an 
average of 3 biological repeats, each an average of 4 technical repeats. Error bars indicate 
variability between biological repeats. 
Of those tested, all vacuolar amino acid transporter deletion strains showed 
approximately halved viability in comparison to the wild type BY4741 strain. However 
the expression of neither Sod1p1-115–GFP or Sod1p1-125 truncations lead to significant 
reductions in viability when compared the GFP control, although strains expressing 
Sod1p1-125 in particular showed a high degree of variability; this suggests the 
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expression of these truncated SOD1 proteins do not lead to a synthetic effect on amino 
acid transporter function, impacting on cell viability.  
3.7.4 Deletion of SOD1 and vacuolar amino acid transporter genes cause amino acid 
auxotrophies. 
Bastow (2013) showed that deletion of the SOD1 gene from yeast BY4741 strain 
caused lysine and leucine auxotrophies, suggesting there may be a link between amino 
acid biosynthesis and SOD1. Due to the synthetic effect observed on growth of 
vacuolar amino acid transporter strains expressing truncated SOD1 proteins, this lead 
to the question of whether vacuolar amino acid transport could also be regulated by 
SOD1, and whether deletion of amino acid transporters may also show imbalances in 
amino acid biosynthesis as described in SOD1 deletion strains.  
Analyses shown in this section use Mass Spectrometry data obtained from Markus 
Ralser’s group in the Department of Biochemistry, University of Cambridge. The Ralser 
group has systematically assessed the total amino acid levels from all strains in the 
yeast deletion collection (Unpublished data). As part of an ongoing collaboration, the 
Ralser group provided data from the SOD1 deletion and all of the vacuolar amino acid 
transporter deletion strains. Cell extracts for Mass Spectrometry analysis were 
prepared from cell extracts of strains harvested during exponential growth phase after 
culture in minimal media.  
For each strain, their Mahalanobis Distance was also determined; Mahalanobis 
Distance gives an indication of outliers in a multivariate dataset, in this case showing 
which deletion strains’ amino acid profiles are significantly different to the average 
obtained across the entire deletion collection data set (4686 strains). A Mahalanobis 
Distance value >30 indicates a significant difference from the average, values over 30 
were  observed in AVT1, AVT3, AVT7, VBA5 and SOD1 deletion strains. The amino acid 
profiles of outlier strains are represented in Figure 3.15, where amino acid levels 
measured in µmols refer to the concentration of each amino acid in the cell extract 
tested, whilst the ‘average’ amino acid level indicates the average concentration of 
amino acids across an entire data set of 4686 strains tested by the Ralser group. 
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Figure 3.16: Amino acid profiles of yeast deletion strains indicating free amino acid 
concentrations in cell extracts detected by Mass Spectrometry. Deletion strains with 
Mahalanobis Distance values above 30. 
It was expected that deletion of a particular amino acid transporter would result in 
increased storage of the types of amino acids generally transported by it; although this 
data suggests this not to be the case. AVT1 transports neutral amino acids but deletion 
results in a significant increase in glutamate storage, a negatively charged amino acid. 
Tyrosine is a neutral amino acid with polar side chains, which appears to be found in 
lower than average concentrations in VBA5 deletion strain, VBA5 being a basic amino 
acid transporter. The SOD1 deletion strain shows significantly decreased levels of 
tyrosine but increased storage of lysine, a basic amino acid.  
To determine whether there was a common phenotype affecting amino acid levels 
between the strains that could be attributed to gene deletion, data for all strains was 
compared for single amino acids. It was hypothesised that leucine concentrations in 
deletion strains may deviate from the average, particularly in the SOD1 deletion strain, 
due to previous evidence showing leucine to have an important role in amino acid 
signalling and transport (Prohl et al., 2001),  and its identification as a regulator of 
amino acid signalling in the presence of mutant SOD1 (Bastow, 2013). However, a 










































































































































54 | P a g e  
 
significant Mahalanobis Distance value or specific phenotype. To further investigate 
the link between SOD1 and amino acid metabolism, Figure 3.16 below shows the 




















Figure 3.17: Lysine and tyrosine amino acid metabolism may be disrupted in a SOD1 deletion 
strain. Mass Spectrometry data of free amino acid concentrations in cell extracts was 
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order from left to right. a) Leucine profiles appear variable but relatively close to the average 
in all strains. b) Lysine concentration is elevated in the SOD1 deletion strain. c) Tyrosine 
concentration is decreased in the SOD1 deletion strain. 
The results show that, as expected, amino acid levels are deregulated by deletion of 
amino acid transporters however, amino acid levels are also perturbed by deletion of 
SOD1, supporting the idea that SOD1 is linked to amino acid transport.  
3.8 Discussion 
3.8.1 Effects of GFP fusion on truncated Sod1p stability and toxicity. 
Seetharaman et al. (2009) suggested that fALS-associated SOD1 mutations prevent 
proper maturation of the mutant protein by disrupting interaction of CCS, responsible 
for copper ion insertion, disulphide bond formation and structural stability of the 
protein. However, it appears that the presence of a structural component in Sod1p 
fragments is likely not related to toxicity, since the SOD1 metal binding loop is located 
between residues 49-84 (Rakhit and Chakrabartty, 2006) (in the human protein, but 
structurally very similar to the yeast orthologue), so is present in its entirety in Sod1p1-
84, Sod1p1-115 and Sod1p1-125. A disulphide bond responsible for stability of the protein 
is formed between residues 57 and 146 so is not present in any of the truncated 
proteins, while the electrostatic loop between residues 122-149 is only partly present 
in Sod1p1-125. The fact that Sod1p1-125-GFP is only able to form a functional and stable 
protein as a result of GFP fusion (Figure 3.8) while Sod1p1-115-GFP is most toxic of all 
tested (Figure 3.3, Figure 3.6), suggests length of Sod1p is the determining factor in 
whether a wild type SOD1 protein is able to function or exhibit toxicity, and the 
difference between these two is determined by only 10 amino acids. Nevertheless, 
further investigation into the presence of the electrostatic loop in wild type Sod1p 
toxicity should be performed, perhaps by creating varying truncations between 
residues 122 and 149 or equivalent in the yeast protein. 
Wright et al. (2013) also showed that structural instability of SOD1 dimers increased 
their tendency to form aggregates. Fusion of GFP lengthens the protein fragment, so it 
may be the case that longer Sod1p fragments cause more toxicity than shorter 
fragments as they are able to aggregate or accumulate within the cell and disrupt 
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functioning. It has been shown that these longer SOD1-GFP fusion proteins do not 
form mitochondrial aggregates (Figure 3.10) but aggregates may form in other areas of 
the cell or accumulation of soluble oligomers may cause toxicity. In the case of Sod1p1-
125-GFP which is not toxic, the added length of GFP appears to stabilize the protein 
which is responsible for its acquired SOD activity.  
3.8.2 SOD1 may play a role in regulation of amino acid transport. 
Sturtz and Culotta (2001) reported that deletion of SOD1 from yeast lead to the 
appearance of metabolic defects, including disrupted methionine and lysine 
biosynthesis. Further evidence has shown SOD1 mutants catalyze oxidative damage of 
human glutamate transporter GLT1, causing inactivation of the transporter and 
subsequent neuronal degeneration (Trotti et al., 1999). Addition of an antioxidant was 
able to reactivate GLT1, suggesting a role of SOD1 in regulation of amino acid 
transport.  The growth differences observed in transporter deletion strains (Figure 
3.13) could be interpreted in one of two ways; firstly, it could be that in a transporter 
deletion strain where no growth defects were observed, the target of toxic Sod1p 
required to cause toxicity was deleted from the genome preventing interaction 
between the two and as a result, the cell does not exhibit growth defects. On the other 
hand, growth defects as a result of toxic Sod1p expression may suggests those 
transporters are necessary for the cell to function properly in the presence of Sod1p1-
115-GFP and could be providing protection to the cell. If the latter is true, an 
explanation for this effect could be that expression of the Sod1p fragment disrupts 
amino acid transport in the cell causing toxicity, and the deleted transporter is 
necessary to regulate transport of trapped amino acids, implicating a role for vacuolar 
amino acid transport in SOD1-mediated toxicity; the relation between SOD1 and amino 
acid transport is also supported by the Mass Spectrometry data showing perturbed 
amino acid levels in the SOD1 deletion strain (Figure 3.17).  Questions arising from this 
are whether the longer truncated SOD1 proteins are able to directly interact with 
vacuolar amino acid transporters to cause dysfunction, or whether its effect on amino 
acid transport is regulated via a signalling pathway. 
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4.1 Introduction 
4.1.1. C. elegans life cycle. 
 The nematode worm C. elegans is widely used in modelling of human 
neurodegenerative diseases. C. elegans exists either as a hermaphrodite, able to 
reproduce asexually or as a male, which are much less common in nature. These 
organisms have a relatively short lifespan and when grown at optimal conditions of 
20°C with plentiful food supply, the adult lifespan is approximately 2-3 weeks. In C. 
elegans development from egg to reproductively functional adult typically takes 3-4 
days and progresses through four larval stages, L1 to L4, before reaching adulthood 
(Figure 4.1). The growth of C. elegans is strongly affected by environmental changes; 
their optimal growth temperature is 20°C, but lowering the temperature to 15°C 
delays its life cycle and gives rise to worms with a larger body size while increasing 
temperature to 25°C accelerates their life cycle and leads to a smaller body size. 
(Devaney, 2005). Under stress conditions such as nutrient starvation, higher than 27°C 
temperatures or other limitations, C. elegans L2 larvae may enter an alternative, stress 
resistant, long-lived ‘dauer’ state, induced by neuroendocrine signalling through the 
dauer pheromone (Hu., 2007; Prahlad and Morimoto, 2009). Worms may remain in 
this form without the need to eat for up to four month and if optimal conditions are 
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Figure 4.1: C. elegans hermaphrodite life cycle. Image from (Strange, 2003).  
4.1.2. C. elegans as an experimental model. 
Metabolic pathways are conserved between C. elegans and mammals, in addition to 
the similarities between their nervous systems; the C. elegans nervous system has 
been thoroughly studied, and complete mapping of their anatomy shows their nervous 
systems are composed of 302 neurones, which use nearly all the same 
neurotransmitters as the mammalian nervous system. Full sequencing of the C. 
elegans genome allowed extensive rational genetic manipulation of worms, with many 
gene deletion and mutant strains now available (Kuwahara et al., 2008; Therrien and 
Parker, 2014). Around 80% of C. elegans genes have orthologues in humans (Lai et al., 
2000; Shaye and Greenwald, 2011). 
C. elegans provides an excellent model organism to study neurodegenerative diseases 
for a number of reasons.  Firstly, genetic manipulation is easily achieved and many 
altered strains are already available in addition to the ease in which RNA interference 
(RNAi) can be performed in worms. RNAi exploits double stranded RNA expressed in 
the bacterial food source of worms and can be used to regulate and silence gene 
expression in C. elegans. Furthermore, the translucent body of C. elegans allows in vivo 
visualisation of anatomy and neurones in a live organism, which is particularly useful 
when studying the progression of neurodegeneration (Li et al., 2013). 
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C. elegans has been used in modelling many human neurodegenerative disorders in 
recent years, including Alzheimer’s, Huntington’s and Parkinson’s diseases. For 
example, evidence obtained in C. elegans has confirmed a role of Huntington’s disease-
associated mutant polyglutamine (polyQ) expansion as a cause of toxicity in multiple 
neurodegenerative disorders. Morley, Brignull and Morimoto (2002) tested this using 
fluorescently-tagged polyQ proteins to observe protein aggregate formation in C. 
elegans, reporting that such aggregate formation and proteotoxicity was slowed in 
long-lived worms but exacerbated by ageing, showing ageing regulates protein 
homeostasis. 
Alzheimer’s disease, characterised by amyloid beta (Aβ) toxicity leading to neuronal 
accumulation of tau protein, has also been modelled using C. elegans. Such studies 
have led to the discovery that over-expression of tau in neurones causes neuronal 
dysfunction comparable to that observed in brains with human patients with 
Alzheimer’s disease or frontotemporal dementia (Stoothoff and Johnson., 2005; 
Wolozin et al., 2011). Link (1995) also modelled β-amyloidosis by producing Aβ in 
muscle cells of C. elegans and later studies by the Link group showed movement 
defects, a growth deficit and premature death as a result of Aβ expression. However, 
other changes mirroring those observed in the brains of Alzheimer’s disease patients 
were observed in C. elegans cells, including increased expression of heat shock and 
pro-apoptotic proteins and evidence of mitochondrial dysfunction (Link et al., 2003; 
Boyd-Kimball et al., 2006; Wolozin et al., 2011). 
C. elegans is also an attractive model for studying motor neurone diseases such as ALS. 
For example, multiple studies have been able to replicate the neuronal degeneration 
and paralysis observed in the ALS condition, in transgenic C. elegans expressing mutant 
human Sod1p (Gidalevitz et al., 2009; Li et al., 2014; Wang et al., 2009; Witan et al., 
2008). Li et al. (2013) found that expression of mutant SOD1 in C. elegans motor 
neurons caused age-dependent motor defects and impaired axon guidance in addition 
to aggregation of mutant SOD1, thereby indicating protein aggregation plays an 
important role in mutant SOD1-mediated neurodegeneration and toxicity. Li et al. 
(2013) also noted that over 80% of mutant SOD1-expressing worms became paralyzed 
by day 12 of the study, while other studies have shown that mutant SOD1 expression 
also causes impaired response to oxidative stress (Oeda et al., 2001). When expressing 
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mutant SOD1 throughout the nervous system rather than just motor neurones, Wang 
et al. (2009) still reported motor defects, accompanied by dysfunctional neuronal 
transmission. Expression of SOD1 mutants in C. elegans body wall muscles however 
showed variability in the tendency of these proteins to aggregate (Gidalevitz et al., 
2009) suggesting that while aggregation occurs most prominently in motor neurones, 
SOD1 mutants can also form protein aggregates in other areas of the body in C. 
elegans. 
In the results presented in the following study, the effects of fALS-associated G85R 
SOD1 mutant or wild type SOD1 over-expression in transgenic C. elegans strains were 
investigated. The G85R SOD1 mutation results in amino acid substitution of arginine 
instead of glycine at residue 85 in the Sod1p primary sequence. This mutation leaves 
the protein highly susceptible to inactivation and also alters metal binding properties 
leading to loss of SOD function in vivo (Nishida et al., 1994). Previous studies from the 
Wang laboratory that created these transgenic strains have shown that G85R mutant 
worms exhibited severe motility defects accompanied by insoluble protein aggregates 
in addition to soluble G85R proteins (Wang et al., 2009).  In the following study, the 
conditions described by Wang et al. (2009) were replicated to observe the effects on C. 
elegans lifespan and determine whether the motor defects reported in the study are 
reliable. 
4.2 Over-expression of G85R mutant and wild type SOD1 reduces the 
lifespan of C. elegans 
Integrated transgenic strains encoding human SOD1-YFP and human SOD1 mutant 
G85R-YFP (Materials and Methods 2.2.3) were first bleached to remove contamination 
(Materials and Methods 2.6.1) then the surviving eggs were grown on standard NGM. 
A plentiful supply of live OP50 bacteria was provided for at least three generations to 
ensure the strains were well fed. L4 larval stage individuals from these strains, along 
with well fed wild type N2 strain were transferred onto fresh OP50-seeded NGM 
media treated with progeny growth inhibitor, 5-fluoro-2'-deoxyuridine (FUDR). The 
larvae were incubated at 25°C for the course of the experiment, with their survival 
being monitored every 2-3 days. L4 stage worms mature to egg-producing adults 
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within one day, so the day following transfer indicated day 1 of the lifespan 
experiment. 
 
Figure 4.2: Adult lifespan of C. elegans is slightly reduced by expression of SOD1 G85R 
mutant when grown at 25°C. a) and b) represent two repeats of the same experiment. Both 
experiments begun with 100 L4 larval stage worms, which were grown on standard solid NGM 
media with live OP50 bacteria and FUDR treatment at 25°C for the course of the experiment. 
Raw data was analysed using Online Application for Survival Analysis (OASIS) software (Yang et 
al., 2011). 
During this experiment, worms were scored as dead if they did not move at all when 
prodded with a worm pick and appeared to have died a natural death, but were 
censored from the experiment if they showed any sign of unnatural death or were lost 
during the experiment. Common reasons for censoring included internally hatched 
larvae often causing death, complete or partial intestinal protrusion from the vulva or 
worms being lost down the edge of the agar. 
a) 
b) 
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The null hypothesis is that worm lifespan would not be affected by expression of fALS-
associated G85R mutant or over-expression of SOD1. Experiment one showed the 
mean lifespan for N2, SOD1-overexpressing and G85R strains were 10.36, 9.03 and 
9.11 days respectively. P-values (Table 4.1) for SOD1 vs G85R were larger than the 
critical value, 0.05, so the null hypothesis was not rejected for these datasets 
indicating there was little significant difference in lifespan between SOD1-
overexpressing and G85R strains. However, N2 vs SOD1 and N2 vs G85R P-values were 
both smaller than the critical value, rejecting the null hypothesis and suggesting there 
is a significant difference in lifespan between control and transgenic strains. In 
experiment two, the mean lifespan for N2, SOD1-overexpressing and G85R strains 
were 10.02, 9.97 and 8.94 days respectively. This time, P-values of N2 vs SOD1 
indicated they were not statistically different, but the lifespan of G85R strain was 
significantly different to both N2 and SOD1 over-expressing strains. 





















      
N2 vs SOD1 23.68 0.0000011  0.01 0.9147 
N2 vs G85R 21.99 0.0000027  8.88 0.0029 
SOD1 vs N2 23.68 0.0000011  0.01 0.9147 
SOD1 vs. 
G85R 
0.04 0.8397  6.51 0.0107 
G85R vs. N2 21.99 0.0000027  8.88 0.0029 
G85R vs 
SOD1 
0.04 0.8397  6.51 0.0107 
 
 Statistical analysis of the data (using OASIS software) from both experiments showed 
that expression of SOD1 G85R mutant did consistently cause a reduction in C. elegans 
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lifespan; conversely, over-expression of SOD1 showed variable effects on lifespan, 
exhibiting statistically significant lifespan reduction only in Experiment 1.  
A potentially important point to note is that the inhibition of progeny growth by FUDR 
is mediated through ingestion. For each experiment, five NGM plates containing 20 
worms each were used for each strain and on plates containing G85R worms, more 
young progeny appeared to hatch consistently than on plates containing SOD1-
overexpressing or N2 worms. Although proper quantification of this phenomenon will 
need to be carried out in the future to investigate its reliability and validity in G85R-
expressing worms, this preliminary observation has two important implications. Firstly, 
the hatching of progeny indicates a physical difference in the G85R worms compared 
to the controls perhaps reflecting that their ability to feed is impaired resulting in a 
reduced intake of FUDR, leading in turn to reduced inhibition of progeny development. 
Secondly, reduced feeding and dosage of FUDR may also impact on lifespan of these 
worms as some evidence indicates FUDR may increase worm lifespan (Rooney et al., 
2014; Aitlhadj and Stürzenbaum, 2010). 
4.3 Investigating the impact of leucine supplementation on SOD1-
mediated motor defects in C. elegans 
4.3.1 Over-expression of SOD1 G85R mutant hinders C. elegans motility but can be 
improved by leucine supplementation. 
During the lifespan experiments (Section 4.2), it was noticed that mutant worms 
appeared to adopt an interesting phenotype in which their movement ability was 
reduced compared to other strains (detailed further in Results 4.3.2). To test this 
observation, motility experiments were performed by growing 30 worms per strain on 
NGM medium and scoring their movement into one of three categories, A, B or C. A-
scored worms exhibited normal motility, B-scored worms slightly reduced motility and 
C-scored worms showing little movement except for head or tail (Materials and 
Methods 2.6.3).  Following results from Bastow (2013) that showed leucine 
supplementation was able to rescue growth defects exhibited by yeast expressing 
fALS-associated SOD1 mutants, varying concentrations (0mM, 1mM, 2mM and 5mM) 
of leucine supplement were also added to the C. elegans medium to investigate 
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whether this would improve their motility.  All experiments in this section were carried 
out using NGM medium seeded with heat-killed OP50 bacteria to prevent metabolism 
of the supplemented leucine by the bacteria, and treated with FUDR to inhibit progeny 
growth. 
When grown at 20°C, G85R worms clearly showed the highest incidence of B-scoring 
with no leucine supplement, indicating slight motor defects. The number of worms 
with slight motor defects in the G85R strain began to increase after day 5 in all 
conditions; however the 2mM leucine condition appeared to reduce the occurrence of 
defects (Figure 4.3c). Severe motor defects were difficult to interpret due to the low 
number of C-scored worms, however the data obtained showed no worms with severe 
motor defects occurring over the course of the experiment when supplemented with 
1mM leucine (Figure 4.4b). In the SOD1 over-expressing strain, the number of worms 
with slight motor defects was greater than the control by day 7 in all leucine 
supplemented conditions, and leucine supplementation also did not reduce the 
occurrence of severe motor defects. Interestingly, higher concentrations of leucine 
also appeared to marginally increase the number of motor defective worms occurring 
in the N2 strain. These results suggest that when grown at 20°C, supplementation with 
low concentrations of leucine can improve motor defects in the G85R worms, but may 
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Figure 4.3: Frequency of C. elegans with slight motor defects on media supplemented with 
increasing leucine concentrations when grown at 20°C. a) shows B-scored worms grown on 
NGM medium with no leucine supplement, b) with 1mM leucine supplemented, c) 2mM 
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Figure 4.4: Frequency of C. elegans with severe motor defects on media supplemented with 
increasing leucine concentrations when grown at 20°C. Experiment a) shows C-scored worms 
grown on NGM medium with no leucine supplement, b) with 1mM leucine supplemented, c) 
2mM leucine supplement and d) 5mM leucine supplement.  
When grown at 25°C, leucine addition resulted in little improvement to motility of 
G85R worms, except at 2mM leucine where occurrence of B-scored worms appeared 
to slow by day 5 compared to other concentrations, despite reaching the same number 
of motor defective individuals by day 7 as the non-supplemented condition (Figure 
4.5c). The 5mM leucine condition showed the greatest incidence of G85R worms with 
slight motor defects. SOD1 over-expressing worms also showed most improvement in 
the presence of 2mM leucine, with lower overall incidence of B-scored worms than the 
N2 strain. Again, few C-scored worms occurred within the tested time period, but the 
results indicate 1mM and 2mM leucine concentrations slightly slow the development 
of severe motor defects in SOD1 over-expressing worms and this may also be the case 
for G85R worms. However, G85R worms showed higher numbers of severe motor 
defective worms in all leucine supplemented conditions by day 7 compared to no 
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leucine supplement (Figure 4.6), suggesting that leucine addition is less able to rescue 
motor defects in worms grown at 25°C.  
 
Figure 4.5: Frequency of C. elegans with slight motor defects on media supplemented with 
increasing leucine concentrations when grown at 25°C. Experiment a) shows B-scored worms 
grown on NGM medium with no leucine supplement, b) with 1mM leucine supplemented, c) 
2mM leucine supplement and d) 5mM leucine supplement.   
    
   
       
d) 
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Figure 4.6: Frequency of C. elegans with severe motor defects media supplemented with 
increasing leucine concentrations when grown at 25°C. Experiment a) shows C-scored worms 
grown on NGM medium with no leucine supplement, b) with 1mM leucine supplemented, c) 
2mM leucine supplement and d) 5mM leucine supplement.     
A longer observation period and larger sample size is necessary to properly investigate 
the ability of leucine supplementation to rescue motor defects and these preliminary 
results give encouragement to do so.       
4.3.2 Leucine supplementation improves thrashing ability in worms expressing ALS-
associated SOD1 mutants. 
SOD1 G85R-expressing worms exhibited a notable phenotype, illustrated in Figure 
4.7.b. This was also observed by Prof. Alan Morgan (University of Liverpool) whose 
group also investigated the effects of human SOD1 G85R mutant expression on C. 
elegans movement in parallel to the research presented here. The mutant worms had 
a tendency to curl up instead of moving freely forward, with reduced movement ability 
when prodded often only moving their head. The Morgan group also quantified this 
motor defect, by performing thrashing assays in which N2, wild type SOD1 over-
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expressing and G85R mutant strains were placed in liquid media and the number of tail 
thrashes by each worm monitored within one minute time periods. They showed that 
SOD1 over-expressing worms gave partially reduced thrashing frequencies in 
comparison to N2 worms, but G85R mutants had severely impaired thrashing ability 
compared to both strains (A. Morgan, personal communication; Figure 4.8). 
Figure 4.7: Motility defective phenotype exhibited by mutant SOD1 C. elegans. Specimens 
over-expressing a) wild type hSOD1 and b) G85R hSOD1 mutant. Image obtained from Prof. 
Alan Morgan (University of Liverpool). 
Figure 4.8: Thrashing ability is severely impaired in G85R hSOD1 mutant worms. Number of 
tail thrashes performed by worms in liquid medium was recorded at one minute intervals for 
each strain. G85R mutant worms showed greatly reduced thrashing ability compared to the 
wild type N2 strain. Data obtained from Prof. Alan Morgan (University of Liverpool). 
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The effects of leucine supplementation on thrashing ability were also explored. When 
supplemented with 1mg/ml, 2mg/ml, 5mg/ml or 10mg/ml of leucine, it was discovered 
that for all strains including N2, thrashing was increased most when a concentration of 
2mg/ml leucine was added to the liquid media (Figure 4.9). Addition of 10mg/ml 
leucine restored thrashing frequency to that of the untreated condition in both N2 and 
G85R strains, suggesting an optimal concentration of leucine is able to improve 
thrashing ability, but higher concentrations will not provide any further increase. 
Despite some improvement, the thrashing ability of G85R mutant worms remained 
very low even in the presence of the optimal leucine supplement. 
 
Figure 4.9: Optimal leucine supplementation improves thrashing ability. Thrashing frequency 
of N2 and SOD1 over-expressing worms is most improved by addition of 2mg/ml concentration 
of leucine. G85R mutant worms also show slight improvement at this concentration. Data 
obtained from Prof. Alan Morgan (University of Liverpool).  
4.4 Mutant SOD1 expression in C. elegans causes vulval defects 
4.4.1 SOD1 G85R mutants show increased occurrence of protruding vulvae. 
Whilst motility experiments were being performed, the occurrence of vulval 
differences in the tested strains became apparent. The number of worms exhibiting 
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protruding vulvae (a phenomenon in which the intestine of the worm begins to 
protrude through the vulva) were monitored and recorded for each strain and motility 
category at 20°C and 25°C incubation, alongside the motility experiment i.e. using the 
same growth conditions and amino acid supplemented conditions. Once the worms 
exhibiting this phenotype died, they were excluded from the experiment. Due to the 
relatively low incidence of B and C-scored worms, and proportionately low numbers of 
worms exhibiting protruding vulvae, the data would be difficult to draw conclusions 
from so only protruding vulvae shown in A-scored, fully motile worms is presented 
here. 
Figure 4.10: Frequency of vulval defects in C. elegans over-expressing wild type and G85R 
mutant hSOD1. Experiment a) shows A-scored worms grown at 20°C and b) shows A-scored 
worms grown at 25°C, both on standard NGM media. SOD1 indicates over-expression of wild 
type hSOD1. 
When grown on standard NGM with no leucine supplement, G85R-expressing worms 
showed significantly more protruding vulvae than other strains, indicating mutant 
SOD1 is likely causing vulval defects, although the same effect is not observed when 
over-expressing wild type SOD1 suggesting a mutant SOD1-specific defect. 
4.4.2 Leucine supplementation reduces the occurrence of vulval defects in worms 
expressing SOD1 G85R mutant. 
The occurrence of protruding vulvae in each strain were also monitored in the 
presence of leucine supplements, to investigate whether leucine addition could 
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improve vulval defects in the same way it appeared to rescue movement ability in 
Section 4.3. 
At 20°C incubation, 2mM leucine supplement appeared to alleviate vulval defects to 
the greatest extent (Figure 4.11b) but at 25°C, 5mM leucine showed the most 
prominent improvement (Figure 4.11f). Conversely, in the SOD1 over-expressing strain 
at 20°C, occurrence of protruding vulvae was relatively low in all leucine 
concentrations except 1mM concentration in which the incidence of protruding vulvae 
was higher than in either N2 or G85R mutant strains by day 5. At 25°C incubation, 
SOD1 over-expressing worms exhibited the lowest frequency of protruding vulvae at 
all leucine concentrations, being equal to or lower than that of N2 worms. These 
findings indicate that SOD1-G85R mutant expression shows some correlation to the 
formation of vulval defects in worms, but that these defects can be improved by 
leucine supplementation. However, wild type SOD1 over-expression generally does not 
cause vulval defects. 
The results also showed that compared to other leucine concentrations and the 
control, A-scored N2 worms growing at 25°C on 1mM supplemented leucine (Figure 
4.11d) medium had a very high incidence of protruding vulvae. Since the medium used 
in these experiments was seeded with dead OP50 bacteria and was prone to 
contamination and growth with live bacteria, worms on these plates required 
transference to fresh medium every few days. It is possible that this is an anomalous 
result caused by these particular worms being somewhat stressed or damaged by the 
frequent movement, affecting their degree of vulval protrusion. 
Another observation was that in the G85R strain grown at 20°C, five worms were 
censored on day 1 of the experiment due to death caused by internal hatching of 
larvae (4 incidences in 1mM leucine condition, 1 in 2mM condition). Internal hatching 
of larvae may indicate further vulval or egg laying defects, or a response to stress. 
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Figure 4.11: Frequency of vulval defects in C. elegans strains grown on leucine-supplemented 
media. Experiments a) to c) show A-scored worms grown at 20°C on NGM media 
supplemented with: a) 1mM leucine, b) 2mM leucine, c) 5mM leucine; Experiments d) to f) 
show A-scored worms grown at 25°C on NGM media supplemented with: d) 1mM leucine, e) 
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4.5 Discussion 
4.5.1 Leucine is able to improve functional defects caused by mutant SOD1 
expression. 
In a study by Wang et al. (2009), it was reported that expression of mutant human 
SOD1 G85R protein caused paralysis of C. elegans. The evidence presented in this 
chapter supports this finding, showing motor defects in the G85R strain and to a lesser 
extent in the SOD1 over-expressing strain, although the motor defective phenotype 
(Figure 4.7b) was only exhibited in the G85R strain suggesting a paralyzing effect 
specific to the mutant protein. Furthermore, lifespan was significantly reduced in G85R 
mutant worms (Table 4.1). It was also discovered in this project that upon addition of 
leucine to G85R worms, their motor defects showed signs of improvement, in some 
cases motility was restored to that of the N2 strain. However, this was not supported 
by thrashing data from the Morgan group. In a similar trend to the motor defects, it 
was found that vulval defects are exhibited in G85R worms but less so in the SOD1 
over-expressing strain, and can be improved by leucine supplementation; these 
findings support evidence by Bastow (2013) that leucine supplementation could also 
rescue growth defects in yeast caused by expression of SOD1 mutants. Leucine is well 
known as a regulator of metabolic signalling, particularly in the TOR pathway nutrient 
sensing pathway (Lynch, 2001). Its apparent role in improving mutant Sod1p-mediated 
defects in C. elegans as described here suggests mutant SOD1 may be exerting toxicity 
through a pathway related to metabolic or amino acid signalling. 
4.5.2 The role of SOD1 G85R mutant in C. elegans reproductive defects and stress 
response. 
During the motility experiments, it was noted that a number of G85R mutant worms 
appeared to have died with internally hatched larvae, a phenomenon that did not 
occur in either SOD1 over-expressing or N2 strains. Trent, Tsung and Horvitz (1983) 
described types of egg laying mutants that showed internal hatching of larvae, and 
categorised them into three phenotypes: muscle defective mutants that also exhibit 
paralysis, vulvaless mutants and dauer-constitutive mutants that form dauers under 
normal, non stress conditions. Considering the incidence of protruding vulvae in G85R 
worms, it would be a plausible suggestion that mutant SOD1 may also cause egg laying 
76 | P a g e  
 
defects in C. elegans. On the other hand, Chen and Caswell-Chen (2003) suggested that 
internal hatching of larvae (or intra-uterine hatching) is also a constitutive stress 
response in which the hermaphrodite mother retains eggs when under starvation 
conditions in order for progeny to use its body as a food source and allow them to 
transition to dauer stage and aid their survival, in a process termed ‘matricide’. In the 
study, it was reported that this process was reversible by addition of food, provided 
the progeny had not fatally damaged the mother. Mosser, Matic and Leroy (2011) 
similarly suggest that internal hatching may be a way of protecting young larvae from 
unfavourable environments. Considering G85R worms were the only strain to exhibit 
this phenotype and growth conditions were not unfavourable, it may suggest 
expression of the mutant hSOD1 protein causes stress to the worms resulting in the 
egg-retention stress response. A logical interpretation may be that oxidative damage 
as a result of disrupted SOD functioning may be causing stress in mutant worms, 
however previous evidence has concluded that mitochondrial oxidative stress is not a 
determining factor in the occurrence of C. elegans matricide (Pestov, Shakhparonov 
and Kornienko, 2011). This may imply that if mutant SOD1 is indeed causing stress-
induced C. elegans egg retention and matricide, it may be by an additional mechanism 
that is a result of mutant SOD1 gain of function. More thorough investigation would be 
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5.1 Developing a model of SOD1-mediated toxicity 
In recent years, it has been proposed that fALS-associated SOD1 mutants exhibit toxic 
effects through a gain of function, not simply loss of SOD activity (Gurney et al., 1994; 
Wang et al., 2005). In the yeast system described in chapter 3 of this project, the 
results portrayed how some truncated SOD1 proteins that had no SOD activity in NBT 
assays caused growth defects in cells expressing them, showing a greater degree of 
growth defects than cells expressing no SOD1 whatsoever (Figure 3.3); this supports 
the idea that a gain of function is responsible for toxicity by truncated SOD1 proteins 
by the same mechanism as mutant Sod1p. In contrast, the longest protein fragment 
Sod1p1-125 when fused to GFP did show SOD activity and was also no longer toxic to 
cells (Figure 3.8; Figure 3.6), the opposite to the effects observed in active SOD1 
mutants such as G37R, which retain SOD activity but still exert toxicity (Lobsiger et al., 
2007); when not fused to GFP, Sod1p1-125 lost its SOD activity but exhibited the 
greatest toxic effect of all the truncated proteins (Figure 3.5; Figure 3.3). This evidence 
suggests that truncated wild type SOD1 proteins do not cause toxicity by the same 
mechanism as mutant SOD1 proteins and implies fragmentation of the protein is not 
the sole cause of toxicity, contrary to the hypothesis proposed by Ghadge et al. (2006). 
This is further supported by the finding that expression of truncated SOD1 proteins in 
yeast does not cause a significant reduction in viability as determined by statistical 
analysis (Figure 3.9) even in those shown to impair cell growth, whereas expression of 
human SOD1 G85R mutant in transgenic C. elegans does cause a reduction in lifespan 
(Figure 4.2). Nevertheless, both yeast and worm models presented developmental or 
functional defects independent of their effects on survival, in yeast this being 
portrayed by growth impairment and in worms, vulval defects and apparent motor 
dysfunction.  
5.2 ALS models show varying mechanisms of toxicity 
One of the aims of this project was to elucidate whether truncated wild type SOD1 
proteins would exhibit the same toxic effects as mutant versions of the protein, and in 
this manner, determine whether the degradation of mutant Sod1p into peptide 
fragments was causing the pathological changes observed in ALS organisms. 
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Ghadge et al. (2006) reported truncated SOD1 expression in chick embryo spinal cord 
neural cells formed cytoplasmic aggregates and caused cells death, the same 
mechanism by which mutant SOD1 exerted toxicity. In this project, it has been shown 
that longer truncated SOD1 proteins cause cellular defects in yeast, resulting in 
significantly slowed growth; this was mirrored in the worm model, which exhibited 
motor and vulval defects in mutant worms that were not exhibited to the same extent 
by over-expression of wild type SOD1. However, defects caused by truncated Sod1p 
did not reduce viability of yeast, whereas mutant SOD1 expression did reduce lifespan 
of worms. It is unclear if despite reducing lifespan in worms, the affected motor 
neurones are actually killed prematurely as a result of mutant SOD1 expression. 
Indeed, Wang et al. (2009) reported toxic mutant SOD1 expression to cause motor 
defects but did not cause early death of motor neurones. A similar finding has been 
demonstrated in Drosophila (Watson et al., 2008). As such, this may suggest a similar 
mechanism occurring in both truncated SOD1-mediated toxicity in yeast and mutant 
SOD1-mediated toxicity in worms, characterised by defective cellular functioning but 
not premature death.  
Furthermore, expression of truncated Sod1p in yeast did not lead to formation of 
mitochondrial aggregates, while expression of both truncated and mutant Sod1p in 
chick embryo spinal cords was shown to form cytoplasmic aggregates (Ghadge et al., 
2006). Animal models have demonstrated increased localisation of mutant Sod1p to 
mitochondria (Vehviläinen et al., 2014) and C. elegans models exhibit accumulation of 
both soluble mutant SOD1 oligomers and insoluble aggregates in motor neurones 
(Wang et al., 2009). The fact that a toxic effect is observed on cells even with 
inconsistent or no aggregation may indicate insoluble aggregate formation is not a 
cause of toxicity. 
5.3 Soluble mutant SOD1 proteins may disrupt mitochondrial function 
Localisation studies looking at fluorescently-tagged truncated SOD1 proteins indicated 
that the fragments do not specifically localise to mitochondria or form aggregates 
(Figure 3.10). However, significant evidence suggests that toxicity is not necessarily 
caused by aggregate formation. Ayers et al. (2014) showed that SOD1 D101N, I113T 
and L144F mutants caused rapidly progressing diseased states despite having low 
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tendencies to form aggregates, while further studies have suggested misfolded soluble 
Sod1p mutants are more toxic than mutants that form insoluble aggregates 
(Brotherton et al., 2012; Karch et al., 2009; Weichert et al., 2014; Zetterström et al., 
2007). Much recent evidence has alluded to the association of mutant Sod1p with 
mitochondria; antibodies specific for misfolded Sod1p showed mutant Sod1p 
association with mitochondrial in spinal cords of rodents (Brotherton et al., 2012; 
Velde et al., 2008), and spinal cords of ALS mice were found to have high levels of 
misfolded soluble mutant Sod1p, the conformation of which would allow translocation 
into mitochondria (Zetterström et al., 2007). Furthermore, Wang et al. (2005) 
discovered that some SOD1 mutants expressed in mice showed association with spinal 
cord motor neurones but not distal fibres, suggesting mutant SOD1 could exert 
neuronal toxicity without directly interacting with the axon. It is possible that this may 
also be the case for truncated SOD1 proteins, which may be exerting mitochondrial 
toxicity through indirect interaction and may also be soluble proteins, hence why 
aggregate formation is not observed. However, the results showed that expression of 
mutant and truncated forms of Sod1p does not impair mitochondrial respiratory 
metabolism (Figure 3.14), suggesting mitochondrial toxicity may not be the main 
mechanism by which these proteins cause defective cell growth. Further work on this 
area could focus on investigating organelle-specific localisation of soluble truncated 
SOD1 proteins in yeast to determine whether it is causing mitochondrial toxicity. 
5.4 The Wnt signalling pathway plays a role in SOD1-mediated toxicity 
The Wnt signalling pathway is highly evolutionarily conserved in animals and remains 
similar even between fruit flies and humans (Inoki et al., 2006). It has roles in the 
regulation of a wide range of signalling pathways and is involved in organogenesis, cell 
fate determination and stem cell renewal in animals. Activation of the Wnt pathway 
begins through a Wnt protein binding to transmembrane Frizzled (Fz) receptors then 
signal transduction to cytosolic Dishevelled (Dsh) protein (Logan and Nusse, 2004); 
after activation by ligands, the Wnt signal branches into three major signalling 
cascades, the Wnt/β-catenin dependent (canonical) pathway or Wnt/β-catenin 
independent (non-canonical) Planar Cell Polarity and Wnt/Ca2+ pathways. In the 
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Wnt/β-catenin dependent pathway, accumulation of β-catenin acts as a co-activator of 
transcription factors in the nucleus.  
Wnt signalling is known to play an essential role in embryonic and cell development 
and disruption of the pathway has been discovered to cause birth defects, most 
notably spina bifida; defective signalling is also implicated in development of many 
types of cancer in addition to skeletal defects (Logan and Nusse, 2004). More recent 
evidence has established a link between decreased Wnt signalling and 
neurodegenerative diseases including Alzheimer’s and Parkinson’s (Inestrosa and 
Arenas, 2010; L’Episcopo et al., 2011). Further research into ALS mice indicates altered 
expression of Wnt signalling molecules within motor neurones (Chen et al., 2012; Li et 
al., 2013; Wang et al., 2013), while Pinto et al. (2013) portrayed how an ALS model 
consisting of NSC-34 motor neurone-like mouse hybrid cells expressing human G93A 
SOD1 mutation showed inhibited Wnt/β-catenin dependent transcription but 
upregulation of BMP/Smad-dependent transcription. Upregulation of the Wnt 
signalling pathway has also shown a protective function in multiple Alzheimer’s disease 
models (Alvarez et al., 2004; Cerpa et al., 2010; De Ferrari et al., 2003; Purro et al., 
2012). In vitro studies showed chemical upregulation of the Wnt pathway by lithium 
chloride lead to an increase in β-catenin and increased neuronal survival in an 
Alzheimer’s disease model (Alvarez et al., 2004; De Ferrari et al., 2003). 
Both canonical and non-canonical Wnt pathways also exist in C. elegans although there 
are some notable differences; in particular, the functioning of β-catenin is shared 
between three homologues in worms, BAR-1, WRM-1 and HMP-2 (Korswagen et al., 
2000; Natarajan et al., 2001). Evidence suggests that the canonical pathway in worms 
using β-catenin homologue BAR-1 functions similarly to the canonical pathway in other 
animals, however pathways using β-catenin homologue WRM-1 function non-
canonically, but differ from non-canonical pathways in other animals, while further 
evidence has implicated the canonical Wnt/BAR-1 pathway in C. elegans vulval 
development. Three types of vulval precursor cells (VPCs) are responsible for 
development of the C. elegans vulva. Vulval development occurs through these main 
stages that are regulated by various genes; the first stage is creation of VPCs, followed 
by fate determination of the VPCs and their proper development and differentiation 
into these fated cells, and finally vulval morphogenesis (Eisenmann, 2005). The 
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discovery that two of the genes involved in fate determination of VPCs, bar-1 and 
mom-3/mig-14, also have roles in the Wnt signalling pathway lead to the conclusion 
that the Wnt pathway may be involved in C. elegans vulval development (Eisenmann 
and Kim, 2000). Vulval development mutant phenotypes often exhibit characteristics 
of hermaphrodites that are unable to lay eggs or show defects such as protruding 
vulvae or vulval eversion (Sternberg, 2005). When expressing SOD1 G85R mutant in C. 
elegans, it was observed that a number died from internal hatching of larvae in 
addition to vulval defects; Results 4.5.2 briefly discussed the possible implications of 
this egg retention, including egg-laying defects and stress-induced egg retention. 
However, these mutant worms remained fertile and most were able to lay eggs. One 
hypothesis was that mutant worms may be physiologically defective and exhibit vulval 
and egg laying defects due to disrupted development of VPCs in forming the egg laying 
system. BAR-1 is known to be involved in specification of vulval precursor cell fates in 
C. elegans by regulation of LIN-39, which is first required during L1 larval stage 
specification of cells into VPCs rather than F fate cells which are no longer able to form 
part of the vulva (Eisenmann et al., 1998). Partial reduction of LIN-39 activity by 
mutation allows some of the ventral epidermal Pn.p cells to develop into VPCs but 
exhibit specification defects. Disrupted Wnt/BAR-1 signalling by mutant SOD1 could 
potentially disrupt vulval cell specification by deregulation of LIN-39. Trent, Tsung and 
Horvitz (1983) reported that the egg laying system is made up of 18 vulval cells, 16 
neurones and 16 vulval and uterine muscle cells. Of the 16 developed vulval and 
uterine muscle cells involved in hermaphrodite egg laying, removal of all 8 uterine 
muscles does not cause a significant defect in egg laying, neither does removal of the 
four vm1 vulval muscles (Schafer, 2005); however, removal of the four vm2 vulval 
muscles stops egg laying completely, suggesting these muscles are required for 
contraction and opening of the vulva to facilitate egg laying. G85R worms do not show 
severe egg laying defects, but it may be that development of vulval or uterine muscles 
are affected by mutant SOD1 expression through disruption of BAR-1 signalling in the 
Wnt pathway.  
An alternative hypothesis was that mutant worms were retaining eggs in response to 
stress; it was previously noted that the G85R mutant strain showed more progeny 
hatching and developing than other strains, suggesting reduced feeding and reduced 
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uptake of FUDR progeny growth inhibitor. Evidence has shown that vulval induction, 
which occurs in L3 stage larvae, can be repressed by starvation conditions and is 
mediated by SRA-13 through the RAS/MAPK pathway (Battu et al., 2003). This suggests 
a potential alternative reason  for the internal hatching of larvae observed in G85R 
worms, which may have not have fully developed vulvae during larval stages as a result 
of decreased feeding ability, leading to egg retention and internal hatching. Thorough 
quantification of egg bloated and defective egg laying worms in a mutant SOD1 strain 
would need to be performed to draw any definitive conclusions. 
The Wnt pathway also functions to regulate mTOR nutrient sensing and protein 
synthesis pathway (mTOR pathway detailed in Chapter 1). Activation of the Wnt 
signalling pathway leads to inhibition of GSK3 which in turn is then unable to 
phosphorylate TSC2. Active TSC2 is then able to activate the mTOR nutrient sensing 
and signalling pathway ultimately leading to protein synthesis and cell growth. An 
interaction between fALS-associated SOD1 mutants and the TOR pathways has already 
been established in yeast by Bastow (2013) and also in mice (Morimoto et al., 2007). 
The results discussed in Chapter 4 illustrate the occurrence of protruding vulva and 
egg-laying defective mutants in C. elegans expressing fALS-associated SOD1 G85R 
mutant, which supports the growing body of evidence portraying disruption of the 
Wnt pathway as a mechanism of mutant SOD1-mediated toxicity. Furthermore, not 
only motility defects but also vulval defects in G85R worms can be improved by 
supplementation of leucine, a potent activator of the TOR pathway (Results 4.3; 
Results 4.4); this implies impaired nutrient sensing or amino acid uptake regulated by 
the TOR signalling pathway, a downstream effect of Wnt signalling disruption. As TOR 
signalling is responsible for regulating protein synthesis and cell growth, disruption of 
the Wnt pathway and downstream effects on TOR signalling may also explain the 
decrease in lifespan observed in G85R worms. However, the Wnt pathway only exists 
in animals, indicating there is an alternative mechanism of SOD1-mediated toxicity 
occurring in yeast. 
5.5 Truncated and mutant SOD1 deregulate amino acid signalling 
A recent study investigating ALS in mice found that SOD1 G93A mutants showed 
abnormal blood plasma amino acid profiles and that and treatment with an inhibitor of 
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glutamine synthetase, an enzyme involved in amino acid metabolism, was able to 
normalise these abnormalities and increase lifespan of mutant mice (Bame et al., 
2014). It was suggested that this deregulation of amino acid levels may provide insight 
into the biochemical basis of ALS. In chapter 3, the role of yeast vacuolar amino acid 
transporters in SOD1-mediated toxicity was investigated. It was shown by Mass 
Spectrometry data that free amino acid levels were perturbed in amino acid 
transporter deletion strain as expected, but also in a SOD1 deletion strain (Results 
3.7.4), suggesting SOD1 may be involved in amino acid regulation. It was also 
demonstrated that truncated SOD1 proteins appear to have a synthetic effect on 
vacuolar amino acid transporters, exhibiting growth defects in some amino acid 
transporter deletion strain (Figure 3.13). From these results, it was suggested that 
truncated Sod1p may be interacting with the transporters and causing toxicity by 
blocking amino acid transport; this could also contribute to the disrupted TOR 
signalling described by Bastow (2013) when expressing SOD1 mutants. In addition to 
this, although growth defects were clearly demonstrated, there was no significant 
reduction in the viability of yeast expressing truncated Sod1p. This suggests amino acid 
transport is not completely inhibited by truncated Sod1p expression but rather 
blocked or defective, or the cells would likely exhibit premature death. Bastow (2013) 
reported that supplementation of leucine was able to significantly improve growth 
defects observed in yeast expressing SOD1 mutants, concluding mutant SOD1 was 
causing toxicity through defective leucine biosynthesis. However, the finding was not 
replicable in this project when G85R mutant worms were supplemented with 
increasing concentrations of leucine. Although optimal concentrations of leucine 
appeared to improve motor function and vulval defects, defects were not reduced to 
the level of the N2 control worms. Furthermore, leucine was readily available in the 
media even without supplementation, suggesting firstly that amino acid uptake into 
cells may be impaired and also that leucine supplementation is not able to eradicate 
the toxicity induced by mutant SOD1 and that there is an addition mechanism of 
toxicity at work; in worms, this may be the disrupted Wnt pathway, deregulating TOR 
signalling as a downstream effect. It is also possible that by a similar mechanism to 
that observed in yeast, the animal equivalent of a vacuole, the lysosome, may be 
affected by mutant Sod1p specifically by interfering with vacuolar/lysosomal amino 
acid influx or efflux and disrupting the nutrient composition of other areas of the cell. 
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This disruption would also deregulate TOR nutrient sensing, where supplementation of 
leucine may improve the observed defects in worms by upregulating TOR signalling 
rather than curing the toxicity. 
5.6 Conclusions and future work 
Yeast vacuole transporter model. 
Following these results, a yeast model is proposed which suggests that the digestion of 
mutant Sod1p into peptide fragments disrupts TOR signalling leading to reduced ability 
of the cell to sense nutrient availability, thus it takes up more tyrosine and less lysine 
than required (Results 3.4) and amino acid auxotrophies are exhibited. It is also 
possible that mutant Sod1p disrupts lysine biosynthesis within the cell leading to this 
auxotrophy. The model also proposes that mutant Sod1p interferes with vacuolar 
amino acid transport, leading to amino acid trapping in compartments of the cell, 
potentially inhibiting accurate nutrient sensing by TOR and exacerbating the problem 
of deregulated amino acid uptake and utilization (Figure 5.1). 
 
Figure 5.1: Yeast model of mutant SOD1-mediated toxicity. 
Worm Wnt pathway model. 
The second model proposes that in C. elegans, mutant Sod1p exerts its toxic effect 
through disruption of the canonical Wnt/BAR-1 signalling pathway leading to vulval 
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development defects and also impaired TOR signalling. Lysosomal amino acid transport 
may also be disrupted. As with the yeast model, impaired TOR signalling may lead to 
amino acid auxotrophies and growth defects that can be improved by upregulation of 
the TOR pathway by leucine addition.  
Future work. 
Following on from the findings presented in this project, better insight into the 
hypothesised mechanisms could be provided through these additional experiments: 
 Wang et al. (2009) discovered that GFP fused SOD1 mutants showed altered 
activity in C. elegans compared to their non-fused counterparts, and the same 
was also shown in this project when expressing truncated SOD1 proteins in 
yeast. Future work should include expression of non-YFP fused SOD1 mutant 
and wild type proteins in C. elegans to determine how this affects their toxic 
effects. 
 Perform lifespan and motility assays using genetically out-crossed SOD1 G85R 
and wild type SOD1 strains that have the same genetic background as the N2 
controls. 
 Truncated Sod1p fragments should be expressed in worms to see if they also 
cause the same defects as SOD1 mutants, and whether they cause motor 
neurone death as observed in chick embryo neural cells by Ghadge et al. 
(2006). 
 Chemical upregulation of the Wnt signalling pathway in C. elegans using lithium 
chloride could be used to determine whether it reduces toxic effects on the 
organism, including motility or vulval defects.  
Further research question include: 
 Does mutant SOD1 cause motor defects in C. elegans through death or 
dysfunction of motor neurones? 
 Does leucine supplementation increase mutant C. elegans lifespan? 
 Is matricide a result of stress or egg-laying vulval defects caused by mutant 
SOD1 expression? 
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